2026 China Innovative Drug Industry: Market Scale, Competitive Structure, and Deep Research Report

Abstract and Core Judgments

Research Background

China's innovative drug industry stands at a historic inflection point. In 2024, the total value of domestic innovative drug License-out deals exceeded $60 billion, with upfront payments of $3.16 billion surpassing total industry R&D fundraising for the first time — these two numbers describe the ongoing transformation more precisely than any macro narrative: China's pharmaceutical industry has shifted identity from "generics powerhouse" to "innovation exporter," a transition formally validated by international capital in 2024.

This report systematically examines China's innovative drug industry landscape, competitive structure, and technology evolution as of 2026. Core data runs through FY2025 annual reports and H1 2026 public disclosures, with a 2026–2030 outlook horizon.

Five Core Judgments

Judgment 1: China's License-out has moved from "historic breakthrough" to "sustained high-speed expansion," with 2025 again exceeding expectations. Full-year 2025 License-out total agreement value reached approximately $135.6 billion (157 transactions), 2.5× the 2024 total of approximately $60 billion (98 transactions). China's share of global out-licensing transactions reached approximately 49%, surpassing the United States for the first time. Upfront payments totaled approximately $7 billion. 2025's surge was driven by parallel scale-up across ADC, bispecifics, GLP-1, and nucleic acid drugs simultaneously — not concentrated in a single deal type — signaling structural stabilization. However, the gap between total agreement value and actual cash received (upfront payments) remains vast; milestone payment realization depends heavily on subsequent clinical outcomes, and the "paper wealth" risk warrants attention. (Source: Pharmcube, January 2026)

Judgment 2: ADC + bispecific antibodies + GLP-1 are structural high grounds, but execution difficulty varies. ADC out-licensing has become highly competitive; technical barriers (site-specific conjugation patents, HPAPI manufacturing qualifications) are the core screening criteria. The commercial validation of bispecifics depends heavily on the final outcome of Akeso's ivonescimab global Phase 3; GLP-1's window of opportunity is "now through 2028," after which next-generation multi-target products will dominate, and single-target GLP-1 domestic pipelines risk being surpassed.

Judgment 3: The ceiling of me-too pipelines has arrived, and the scarcity premium of first-in-class is now being priced. The reality of ten domestic PD-1 monoclonals competing for the same insurance reimbursement pool is already reflected in the market as competitive price pressure at each negotiation round. In 2024, capital markets visibly concentrated valuation premiums on companies with first-in-class characteristics (BioAtla/BMS deal, Akeso's bispecific out-licensing), while vast numbers of me-too targeted therapy candidates remain under valuation adjustment. In the next five years, innovation quality will increasingly be screened by the combined judgment of researchers, clinicians, and investors.

Judgment 4: China's CXO global standing is at a critical window, with BIOSECURE Act being the most important external uncertainty. If enacted, companies like WuXi AppTec will face substantial contraction of their US-facing business, but domestic R&D demand growth and substitution from European/Asia-Pacific clients will partially cushion the impact. The CXO sector will undergo a "de-US-dependency" structural adjustment in 2025–2030; companies that complete this adjustment will retain global competitiveness.

Judgment 5: China's journey from "follow-on innovation" to "original innovation" is not complete, but the pace is accelerating. The 2024 out-licensing deals centered on ADC and GLP-1 — areas where China has genuine technological accumulation. In truly frontier areas such as CNS, gene editing, and PROTAC, however, Chinese originality still trails US/European tier-one institutions. Whether China can secure global standing in first-in-class target discovery over the next decade is the core question determining the industry's ceiling.

Seven Key Data Points (Updated to FY2025)

• China's innovative drug market 2025E: approximately RMB 170–200 billion (pure innovative drug scope); projected RMB 380–420 billion by 2030 (neutral CAGR 15–18%);
• License-out 2025: 157 transactions, approximately $135.6 billion (total agreement value, +2.5× YoY); upfront payments approximately $7 billion; China first surpassed US at ~49% global share (Source: Pharmcube, January 2026);
• Hengrui Medicine FY2025: total revenue RMB 31.629 billion (+13.0%), innovative drug revenue RMB 16.342 billion (+26.1%), net profit RMB 7.711 billion (+21.7%), R&D investment RMB 8.724 billion (27.6% of revenue);
• BeiGene FY2025: zanubrutinib global sales RMB 28.067 billion ($3.85 billion) (+48.8%), #1 BTK inhibitor globally, first-ever GAAP full-year profit (net profit RMB 1.461 billion), total revenue RMB 38.225 billion (+40.5%);
• Legend Biotech Carvykti FY2025: first three quarters $1.332 billion, full year estimated $1.8–2.0 billion (+85%+ YoY), Q3 quarterly record $524 million;
• NMPA 2025 set a record with 120 new drug approvals (excluding TCM), domestic products exceeding 50% for the first time (63 drugs); 50 Class 1 innovative drugs approved;
• 2025 National Medical Insurance Negotiation added 114 new drugs, with an 88% success rate (highest in 7 years), 50 Class 1 innovative drugs included; cumulative insurance payments for negotiated drugs exceeded RMB 460 billion.

Report Structure

This report organizes twelve chapters as follows:

Chapter 1 starts from definitions and classifications, building foundational knowledge of the innovative drug conceptual framework and industry chain landscape. Chapter 2 takes a global perspective, analyzing 2024 profiles of eleven international pharmaceutical giants including Pfizer, Merck, and Eli Lilly. Chapter 3 systematically analyzes the external environment through PEST dimensions. Chapter 4 quantifies Chinese market scale, distinguishing two statistical scopes (RMB 150–170B vs. RMB 257.6B). Chapter 5 breaks down each segment of the industry chain, from CRO, CDMO, and clinical trial systems to investment and financing ecosystems. Chapter 6 covers competitive landscape and major enterprises in depth. Chapter 7 introduces the spatial dimension, examining five core clusters and the systemic challenge of identifying mid-stream manufacturing partners. Chapter 8 provides deep analysis of eight sub-tracks: PD-1/ADC/GLP-1/bispecifics/CAR-T/CDK4/6/autoimmune/rare diseases. Chapter 9 systematically reviews key technology trends. Chapter 10 comprehensively examines risks. Chapter 11 provides quantitative forecasts for 2026–2030. Chapter 12 presents overall conclusions with a supply chain identification perspective.

Chapter 1　Definitions, Classifications, and Industry Chain Overview

1.1　Definition and Regulatory Classification of Innovative Drugs

In China's regulatory framework, the National Medical Products Administration (NMPA) classifies chemical drugs into six registration categories. Class 1 chemical drugs are "innovative drugs not yet approved domestically or internationally" — new chemical entities (NCEs) globally — and carry the highest regulatory recognition and market exclusivity protection. Class 2 are improved new drugs; Class 3 are drugs approved abroad but not yet in China; Class 4 are generics.

Biologics are similarly stratified: Class 1 biologics are innovative biologics (including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and other globally first-in-class molecules), the most closely watched category in capital markets; Class 2 are improved biologics; Class 3 are biosimilars.

Three innovation tiers require distinction: Me-too drugs pursue similar targets with similar structures to circumvent patents and accelerate market entry. This approach dominated China's first innovation wave (2010–2020), generating multiple domestic PD-1 monoclonals and first-generation domestic EGFR inhibitors. Me-better drugs achieve differentiated improvements on known targets or mechanisms — extended half-life, reduced toxicity, expanded indications, or modified dosing. Innovent's mazdutide (IBI362) as a dual GLP-1/GCG receptor agonist exemplifies this direction versus Novo Nordisk's semaglutide. First-in-class drugs are developed against novel, previously unvalidated targets — the highest form of innovative drug development, with the highest patent barriers and the greatest clinical risk.

In 2024, NMPA approved 90 new drugs, with domestic products comprising approximately 44%. However, among these domestic drugs, the proportion constituting truly global-first NMEs/NBEs remains limited, mostly concentrated in me-better or best-in-class directions.

1.2　Classification by Therapeutic Area

Oncology is the most active area globally, accounting for over 40% of all innovative drug R&D pipelines. China is among the world's highest-incidence cancer countries; lung, stomach, colorectal, liver, and breast cancers constitute the most densely developed indication clusters for Chinese innovative drugs. PD-1/PD-L1 inhibitors, ADCs, and targeted small molecules (EGFR/ALK/BTK/CDK4/6) are the core technology directions.

Autoimmune disease constitutes the second-largest innovative drug market globally at approximately $160 billion. Rheumatoid arthritis, IBD, psoriasis, ankylosing spondylitis, and SLE all have large active pipelines. After the TNF-α inhibitor era (adalimumab/etanercept), antibody drugs targeting IL-6, IL-17, IL-23, IL-4/13, and BLyS/APRIL have become mainstream. Domestically, RemeGen's telitacicept (BLyS/APRIL dual inhibition) in lupus is a representative commercialized domestic autoimmune innovative drug.

Metabolic disease has undergone historic restructuring due to GLP-1 drugs. Type 2 diabetes and obesity/overweight have become the world's largest chronic disease market, with Eli Lilly's tirzepatide and Novo Nordisk's semaglutide pushing the GLP-1 market to approximately $50–60 billion in 2024. China has nearly 140 million diabetes patients.

Rare diseases receive special policy incentives under orphan drug designation: R&D subsidies, extended exclusivity, and accelerated review in Europe and the US. SinoCell Technology's recombinant human coagulation factor VIII (hemophilia A) ended China's complete reliance on imported clotting factor concentrates.

1.3　Classification by Technology Platform

Small molecule chemical drugs remain the dominant class, with molecular weights typically below 500 Da, orally convenient, and with relatively mature manufacturing processes. Key protein kinase inhibitors include EGFR inhibitors (erlotinib/gefitinib/osimertinib), BTK inhibitors (ibrutinib/zanubrutinib), and ALK inhibitors (crizotinib/alectinib).

Monoclonal antibodies (mAbs) are the primary biologic class at approximately 150 kDa, typically administered intravenously or subcutaneously. PD-1/PD-L1 monoclonals and anti-HER2 antibodies (trastuzumab/pertuzumab) are the most mature commercial categories.

Antibody-Drug Conjugates (ADCs) combine monoclonal antibody targeting specificity with cytotoxic small molecule payload killing power, linked via a linker. Called "biological missiles," ADCs theoretically deliver chemotherapy drugs precisely to tumor cells with reduced systemic toxicity. The global ADC market in 2024 is approximately $10–12 billion, exemplified by AstraZeneca and Daiichi Sankyo's Enhertu (DS-8201, targeting HER2), with annual sales exceeding $5 billion.

Bispecific antibodies simultaneously bind two different targets. The most notable application is T cell engagers (TCE), directing immune cells to tumor cells via simultaneous binding of tumor antigens and CD3 on T cell surfaces. Akeso's ivonescimab (AK112, PD-1/VEGF bispecific) and cadonilimab (AK104, PD-1/CTLA-4 bispecific) are China's most watched bispecific clinical products.

CAR-T cell therapy represents the paradigm shift from biologics to cell gene therapy. CAR-T products are priced at RMB 1–1.2 million per dose; the global CAR-T market is approximately $4–5 billion in 2024.

PROTAC (Proteolysis Targeting Chimera) is a new strategy for targeting previously undruggable proteins by recruiting E3 ligases to mark target proteins for proteasomal degradation, overcoming resistance from point mutations.

1.4　Industry Chain Overview

The innovative drug industry chain spans basic research, clinical development, manufacturing, and commercialization, with specialized participants at each stage.

Upstream (Basic Research and Tool Layer): Target discovery and validation, molecular design, compound screening, and preclinical studies (pharmacology/toxicology/pharmacokinetics). Chinese universities and CAS systems have accumulated substantial foundational target research, but the "death valley" from academic discovery to drug development remains significant.

Midstream (Clinical Development and Manufacturing): Phase I clinical (safety, 20–80 subjects, 1–2 years), Phase II (proof of concept, 100–300 subjects, 2–4 years), Phase III (registrational, hundreds to thousands, RCT design, 3–5 years), NDA/BLA submission, and CMO/CDMO manufacturing outsourcing. Full-chain success requires approximately $5–15 billion in cumulative investment.

Downstream (Commercialization Layer): NDA/BLA review and approval, hospital formulary access, medical insurance negotiation, commercial promotion, drug distribution (distributors/DTP pharmacies), and retail/internet pharmacies.

1.5　30-Year Evolution of China's Innovative Drug Sector

China's innovative drug history is a story of evolution from near-complete generics dependence toward original innovation over three decades.

1990s: The era of generics — raw API export as the core capability.

2000–2010: Improved-type innovation sprouts, with some major pharma companies beginning improved formulation/combination explorations.

2010–2015: Biosimilars rise with companies like Henlius and 3SBio pioneering trastuzumab and bevacizumab biosimilars, establishing antibody engineering and large-scale cell culture capabilities. BeiGene, Innovent, and other new Biotechs begin fundraising.

2015–2018: NMPA review reform (the "722 self-examination" withdrawing low-quality generic applications), Priority Review, and the Marketing Authorization Holder (MAH) system. MAH was especially important: decoupling registration from manufacturing allowed Biotechs to hold drug approvals while outsourcing to CMOs, greatly lowering barriers to innovation entrepreneurship.

2018–2022: PD-1 commercialization — sintilimab (Innovent), camrelizumab (Hengrui), toripalimab (Junshi), tislelizumab (BeiGene) densely market. China enters the "domestic PD-1" era.

2022–2024: License-out eruption, the inflection from me-too to first-in-class. 2024 total License-out exceeds $60 billion, with upfront payments exceeding industry R&D fundraising for the first time.

1.6　The Intellectual Property System for Innovative Drugs

Patent protection provides the market exclusivity that justifies the high cost of innovative drug R&D. Drug patents typically include substance patents (compound structure, the core patent, typically 20 years from filing), manufacturing method patents, formulation patents, and use patents (new indications).

China's drug patent protection system has been rapidly improved over the past decade. The 2021 Fourth Amendment of the Patent Law introduced a patent linkage system (generics applicants must make patent declarations), patent protection term extension (up to 5 years for review-related reductions), and a data exclusivity period (6 years). These improvements directly enhanced China's innovative drug R&D return expectations.

Chapter 2　Global Landscape and International Pharmaceutical Giants

2.1　Global Innovative Drug Market Size and Structure

The global innovative drug market in 2024 is approximately $1.3 trillion. From a geographic perspective, the United States remains the largest single market, accounting for approximately 45–48% of global sales. European five major countries account for approximately 18–20%, Japan approximately 5–6%, and China approximately 5–7%, with share increasing rapidly.

By therapeutic area, oncology accounts for approximately 25–30% of global innovative drug sales, immunology/autoimmune approximately 15–20%, CNS approximately 10%, and cardiovascular/metabolic diseases approximately 15% (rising rapidly due to GLP-1).

China's position in the global innovative drug value chain is undergoing a historic shift. Prior to 2024, Chinese pharma companies primarily played three roles: API manufacturers, biosimilar developers, and recipients of MNC local adaptations. After 2024, China has begun participating in the global innovative drug value chain as an original molecule exporter. The $60 billion License-out figure in 2024 marks a structural turning point.

2.2　Pfizer — Post-COVID Restructuring

Pfizer's 2024 revenue is approximately $58 billion. After COVID-19 vaccine (BNT162b2) and Paxlovid's explosive sales period, Pfizer's 2024 core growth pillars are its oncology and ADC lines: Padcev (enfortumab vedotin, urothelial carcinoma ADC, acquired with Seagen), Xtandi (enzalutamide, prostate cancer), and Nurtec (rimegepant, migraine CGRP inhibitor). The 2023 acquisition of Seagen for approximately $43 billion made Pfizer one of the strongest ADC franchises globally.

2.3　Merck — The Keytruda Empire at Its Apex

Merck (NYSE: MRK) 2024 revenue approximately $63 billion. Its most critical driver is a single drug: pembrolizumab (Keytruda), with 2024 global sales of approximately $25 billion — historically the highest-selling single drug.

Keytruda has been approved for over 40 indications, covering NSCLC, melanoma, head and neck squamous cell, bladder, endometrial, colorectal, and gastric cancers among others. Keytruda's approaching patent expiry (around 2028) is a core driver of Merck actively seeking License-in of Chinese innovative drug assets.

Merck's China innovative drug strategy: cooperation with Kelun-Biotech (6990 HK), with cumulative agreements totaling approximately $11.821 billion across multiple ADC candidates — a systematic bet on an entire Chinese ADC platform, the most typical case of MNC systematically backing Chinese ADC technology.

2.4　Roche — The HER2 Empire and Transformation

Roche (SIX: ROG) 2024 revenue approximately $60 billion. Roche pioneered HER2-targeted therapy with trastuzumab (Herceptin), pertuzumab (Perjeta), and Kadcyla (T-DM1, ADC), but trastuzumab patent expiry around 2020 led to significant biosimilar erosion. In multiple sclerosis, ocrelizumab (Ocrevus) is Roche's fastest-growing 2024 product, with annual global sales approximately $7 billion.

2.5　Novartis — Steady in CDK4/6 and Heart Failure

Novartis (NYSE: NVS) 2024 revenue approximately $46 billion, with growth driven by Kisqali (ribociclib, CDK4/6 inhibitor, HR+/HER2- breast cancer, 2024 sales exceeding $2.5 billion), Entresto (sacubitril/valsartan, ARNI, heart failure, approximately $7.5 billion in 2024), and Kesimpta (ofatumumab, CD20, multiple sclerosis). Novartis' China connection: acquisition of siRNA from Shimai Biopharmaceutical with $185 million upfront — the largest single out-licensing deal for Chinese nucleic acid drugs in 2024.

2.6　AstraZeneca — ADC and Deep China Entanglement

AstraZeneca (NASDAQ: AZN) 2024 revenue approximately $54 billion, the MNC with the deepest China presence and tightest connection to China's innovative drug ecosystem.

Enhertu (DS-8201, trastuzumab deruxtecan), co-developed with Daiichi Sankyo, had 2024 global sales exceeding $5 billion. Using "bystander effect" mechanism and third-generation ADC technology, Enhertu has become the new standard for HER2-targeted therapy and achieved a historic breakthrough in HER2-low breast cancer.

Osimertinib (Tagrisso): Third-generation EGFR inhibitor targeting T790M resistance mutations, approximately $6 billion in global annual sales, with China as one of the largest single markets (high lung cancer incidence).

AstraZeneca's China innovative drug strategy is among the most aggressive of any MNC: it has established a dedicated China R&D center (Shanghai) with over 3,000 R&D staff, deeply participating in early-stage pipeline collaborations with local Biotechs.

2.7　Eli Lilly — The GLP-1 Supercycle Beneficiary

Eli Lilly (NYSE: LLY) 2024 revenue approximately $45 billion, the fastest-growing major pharma company by market cap over the past three years. The driving force is highly concentrated in tirzepatide (Mounjaro/Zepbound, dual GLP-1/GIP), with 2024 combined indication sales of approximately $17.6 billion.

Lilly's China innovative drug connection in the GLP-1 track: licensing agreement with Innovent for mazdutide (IBI362, GLP-1/GCG dual target), $250 million upfront, total up to $1.91 billion. Lilly's strategic logic: expand GLP-1 pipeline diversity at lower cost, covering China-specific indication development.

2.8　Novo Nordisk — Semaglutide's Global Dominance

Novo Nordisk (CPH: NOVO-B) 2024 revenue approximately $44 billion. Semaglutide (Ozempic/Wegovy) achieved 2024 global combined sales exceeding $20 billion — one of the world's best-selling drugs.

2.9　Johnson & Johnson — Multiple Myeloma and CAR-T

J&J (NYSE: JNJ) 2024 revenue approximately $90 billion (including medical devices; Janssen pharma approximately $58 billion). Core growth engines include daratumumab (Darzalex, CD38 mAb, multiple myeloma, approximately $10 billion in 2024 global sales), and co-commercialization with Legend Biotech of ciltacabtagene autoleucel (Carvykti): global's first BCMA CAR-T, approximately $500–600 million in 2024 global sales.

2.10　AbbVie — The Post-Humira Relay

AbbVie (NYSE: ABBV) 2024 revenue approximately $56 billion. With adalimumab (Humira) US patent expiring in 2023, the relay is now clearly established: Skyrizi (risankizumab, IL-23p19, psoriasis/IBD, 2024 sales exceeding $9 billion) and Rinvoq (upadacitinib, JAK1 selective, RA/IBD/psoriatic arthritis, 2024 sales exceeding $5 billion) have together surpassed Humira's peak annual sales.

2.11　BMS — Pioneer of Tumor Immunotherapy

Bristol Myers Squibb (NYSE: BMY) 2024 revenue approximately $47 billion. Opdivo (nivolumab, PD-1) is the co-founder of modern tumor immunotherapy with Keytruda. Eliquis (apixaban) is the world's best-selling anticoagulant (annual sales exceeding $12 billion). The BMS-BioAtla transaction: acquiring BL-B01D1 (EGFR×HER3 bispecific ADC) from BioAtla with an $800 million upfront payment (received February 2024), total $8.4 billion including milestones — the record single-transaction upfront for a domestic Chinese innovative drug.

2.12　Takeda — Specialty Strategy in Rare Disease and GI

Takeda (TYO: 4502) 2024 revenue approximately $19 billion, Japan's largest pharma company. Entyvio (vedolizumab, α4β7 integrin mAb, IBD, approximately $5 billion in 2024 annual sales) and Takhzyro (lanadelumab, KLKB1 antibody, hereditary angioedema) are core products.

2.13　China's Coordinates in the Global Value Chain

Three structural judgments emerge from comparing Chinese innovative drug sector to the above MNC landscape:

First, the global innovative drug R&D centers remain primarily in North America (Boston/San Francisco Bay Area/San Diego) and Europe (UK/Switzerland/Germany); China is building a third pole but has not yet joined the first tier in R&D density.

Second, MNCs are shifting their China asset acquisition logic from "clinical follower" to "platform bet". The Kelun-Biotech/Merck $11.8B ADC platform deal, BioAtla/BMS $8.4B bispecific ADC deal, and Innovent/Lilly GLP-1 deal signal that MNCs are systematically acquiring Chinese original technology platforms, not just conducting clinical bridging.

Third, China's innovative drug sector is occupying a unique position: high cost-effectiveness preclinical research capability (CRO ecosystem) + rapid iteration molecular diversity (large numbers of Biotechs exploring in parallel) + massive domestic clinical trial resources (large patient pool, relatively lower cost) make China an important global innovative drug pipeline supplier.

2.14　Global Pipeline Scale

As of 2024, global innovative drug pipelines total over 20,000 (including preclinical through Phase 3), with approximately 6,000–7,000 in active clinical stages. Chinese pipelines have rapidly increased from approximately 5% of the global share in 2018 to approximately 12–15% in 2024, making China the third-largest source of innovative drug pipelines globally.

2.15　Global Drug Pricing System

The global innovative drug pricing system varies enormously across markets. Keytruda's US annual treatment cost is approximately $170,000–180,000; in China's reimbursement formulary, the annual cost is approximately RMB 30,000–50,000 (approximately $4,000–7,000) — a difference of 25–40×. This pricing gap is why the US represents approximately 45–48% of the global market.

China's medical insurance negotiation prices are among the world's lowest, and while this ensures greater patient access through volume-for-price, it creates challenges for out-licensing negotiations where MNCs benchmark against global best available prices.

2.16　Emerging Market Opportunities

Beyond the five traditional markets (US/Europe/Japan/China/South Korea), India, Brazil, Southeast Asia, the Middle East, and Africa are becoming new expansion directions, particularly for Chinese Biotechs. Singapore (HSA) serves as the Southeast Asian regulatory reference market; Gulf Cooperation Council (GCC) countries (Saudi Arabia/UAE/Qatar) offer high payment capacity.

2.17　Strategic Evolution of the Global Innovative Drug Landscape

R&D division: The US Boston/Bay Area/San Diego clusters remain highest-density globally; Europe maintains traditional pharma strength; China is forming an Asian third pole centered on Shanghai Zhangjiang/Suzhou BioBAY. AI pharmaceutical tools are reducing geographic barriers.

Manufacturing division: ADC specialty CDMO, CGT CDMO, and mRNA production are forming global specialized divisions. European/US large CDMOs (Lonza/Catalent) handle highest technical barrier products; Chinese CDMOs (WuXi Biologics/Kelun) leverage cost advantages for mid-tier products; Samsung Biologics is rapidly rising with scale efficiency.

2030 core judgment: Eli Lilly and Novo Nordisk will continue dominating global market cap rankings on GLP-1; ADC will become the most important oncology treatment platform after PD-1 (approximately $30–35B market); AI pharma will produce key clinical milestones in 2026–2028. China Biotech's share in the global innovative drug value chain is projected to rise from current 5–7% to 10–15% by 2030.

Chapter 3　PEST Environmental Analysis

3.1　Political and Policy Environment

3.1.1　Medical Insurance Negotiation — The Double-Edged Sword of Price-for-Volume

The National Healthcare Security Administration's normalized drug reimbursement negotiation mechanism, entering its ninth edition in 2024, has achieved a negotiation success rate of approximately 73.5%, average price reduction of approximately 63.5%, cumulative reimbursement of over RMB 35 billion, driving related drug sales exceeding RMB 51 billion.

The core design logic is "volume-for-price": innovative drugs enter the formulary at significantly below-application prices in exchange for access for all 1.89 billion insured persons. For hospital-channel oncology innovative drugs, this mechanism typically delivers 3–5× volume increase sufficient to offset the price reduction. Hengrui's camrelizumab, despite successive negotiation price cuts, achieved cumulative sales exceeding RMB 20 billion, validating this logic.

However, the mechanism also raises concerns about compressed innovation returns. An average 63.5% price cut means innovative drug companies face significant constraints on pricing autonomy, making it difficult to replicate the $25 billion annual sales ceiling of Keytruda in the US market.

3.1.2　Volume-Based Procurement (VBP) Exemption — The Institutional Shield for Innovative Drugs

China's national organized drug procurement (VBP) since 2019 has focused primarily on generic drugs, using competitive bidding to drive generic prices to floor levels. The policy explicitly signals: "VBP does not include innovative drugs, innovative drugs are not VBP."

This exemption has profound industrial significance: protecting innovative drug pricing power during patent periods, maintaining reasonable R&D return expectations, and preventing generic competition from directly impacting innovative drugs.

3.1.3　Full-Chain Support Policy for Innovative Drugs

In 2024, innovative drugs were included in the State Council's Government Work Report for the first time, with multiple dedicated policy documents forming a full-chain support framework. Key measures include continued expansion of Priority Review and Breakthrough Therapy designation pathways, MAH system improvements, National Medical Center construction supporting high-quality clinical trial infrastructure, and differentiated support for biopharmaceutical industrial parks in Shanghai, Suzhou, Beijing, and Guangzhou.

3.1.4　US IRA and International Policy Transmission

The Inflation Reduction Act (IRA, 2022) allows the federal government to negotiate prices for Medicare drugs for the first time. Pembrolizumab (Keytruda) has been confirmed on the negotiation list. The IRA's transmission effect on Chinese innovative drug out-licensing is indirect but real: if MNC core product US pricing is subject to government control, their expected return from acquiring Chinese innovative drug assets will be correspondingly reduced.

3.2　Economic Environment

China's 2024 GDP is approximately RMB 127 trillion, maintaining approximately 5% growth. As a critical component of healthcare spending, Chinese residents' healthcare expenditure continues to grow with rising income levels.

Financing environment: 2024 China biopharmaceutical primary market financing experienced significant cooling, with estimated deal volume of approximately RMB 55–65 billion. Funds concentrated notably toward later-stage projects with clinical data. For the first time historically, 2024 Chinese innovative drug License-out upfront payments ($3.16 billion) exceeded same-year R&D fundraising ($2.71 billion), representing a historic inflection in the capital cycle logic.

3.3　Social Environment

China is rapidly entering deep aging: approximately 300 million people over 60 in 2024 (approximately 21.1% of population), projected to reach 400 million by 2035. Aging brings closely correlated disease spectrum changes: cancer incidence increases with age; metabolic disease (type 2 diabetes, hypertension, hyperlipidemia) increases with age; autoimmune diseases are being increasingly diagnosed due to improving medical awareness.

Patient access and payment willingness present structural challenges. CAR-T products priced at RMB 1–1.2 million/dose remain far above basic medical insurance payment capacity.

3.4　Technology Environment

NMPA's accelerated review pathways — Priority Review, Breakthrough Therapy Designation, and Conditional Approval — have become standard rather than exceptional for innovative drug market entry. 2024 NMPA approved 14 Breakthrough Therapy designations and 32 Priority Reviews.

Key global technology trends reshaping the competitive landscape include: AI pharmaceutical tools (AlphaFold2/3's revolutionary protein structure prediction breakthrough), ADC generational iteration (from first-generation random conjugation to third-generation site-specific + novel linker + novel payload, precise DAR 4–8), mRNA technology platform expansion, and gene editing therapy milestones (first CRISPR drug Casgevy FDA approved for sickle cell disease in 2023).

3.5　Systematic Upgrade of Biopharmaceutical Infrastructure

Gene sequencing and precision medicine infrastructure: China holds a unique global scale advantage in gene sequencing. BGI and its MGI subsidiary are major global suppliers of sequencing equipment and services. The domestic precision oncology market (NGS testing, liquid biopsy, companion diagnostics) is approximately RMB 8–10 billion in 2024.

High-quality clinical trial upgrades: China's GCP system, since the 2020 revised standard aligned with ICH E6(R2), has been steadily convergingwith international standards. The simultaneous China-US IND (dual-track IND) strategy promotes more and more Chinese Phase I/III trials to be designed per FDA standards.

3.6　Comprehensive PEST Assessment

The external environment for China's innovative drug industry in 2024–2030 is overall "strong policy support + economically neutral to positive + strong social demand + accelerating technology evolution" — a rare configuration of four dimensions pointing in the same positive direction.

3.7　"14th Five-Year Plan" Review and "15th Five-Year Plan" Outlook

The "14th Five-Year Plan" (2021–2025) achieved significant milestones: annual domestic innovative drug NMPA approvals rose from approximately 20 (2020) to approximately 40 (2024); historical review backlogs were substantially cleared; over 100 innovative drug companies accessed capital through HK Stock Exchange Chapter 18A and STAR Market; License-out grew from approximately 10 transactions/year in 2019 to approximately 98 transactions/year in 2024 — a roughly 10× increase.

"15th Five-Year Plan" policy expectations (2026–2030): further efficiency improvement in review and approval (NDA target under 6 months for Priority Review); medical insurance payment reform deepening (value-based payment trials for gene therapy/CAR-T); international regulatory convergence (gradual data mutual recognition under ICH framework); continued domestic "made in China" substitution investment in key raw materials (single-use bioreactors, culture media, ADC linker intermediates).

Chapter 4　Chinese Market Scale and Operations

4.1　Statistical Scope Clarification

The Chinese innovative drug market size figure varies significantly across different research reports. Two key scopes:

Scope 1: Pure innovative drugs — NMPA Class 1 chemical drugs and Class 1 biologics (globally first-in-class NCE/NBE), excluding biosimilars and generics. Under this scope, China's 2024 market is approximately RMB 150–170 billion — this report's core benchmark.

Scope 2: Broad innovative drugs — including improved new drugs (chemical Class 2). Under this scope, 2024 market is approximately RMB 257.6 billion, +22.6% YoY. This scope is used by some industry consulting firms.

The scope difference originates from China's drug registration classification system not fully corresponding to the FDA/EMA NME concept. Domestic Class 2 improved new drugs might be classified as "improved generics" rather than true innovative molecules in international terminology.

This report uses Scope 1 (RMB 150–170 billion, 2024) as the baseline, while citing Scope 2 (RMB 257.6 billion) as an industry perception reference.

4.2　Market Growth Drivers

Multiple structural forces are resonating to drive high-speed growth of China's innovative drug market.

Medical insurance "volume-for-price" mechanism: Average ~63.5% price reduction in exchange for reimbursement access, multiplying the addressable patient population by orders of magnitude. Camrelizumab's successive negotiation price cuts but cumulative sales exceeding RMB 20 billion validates this logic.

Structural transition driven by VBP: VBP compressing generic prices forces large pharma companies to transition toward innovation, directly driving major domestic companies including Hengrui, Qilu, CSPC, and Yangtze River to accelerate innovative drug transformation.

Rigid demand growth from population aging: China's approximately 4.8 million new cancer cases annually, with lung cancer approximately 1.06 million (global most), constitutes the largest single market basis for oncology innovative drugs.

Diagnostic rate improvement: NGS testing in tumor patients (EGFR/ALK/KRAS etc.) is expanding, enabling more patients to receive precision targeted drug matching. EGFR mutation positive rate in East Asian lung cancer patients is approximately 40–50% (significantly higher than Western 10–15%), directly expanding the addressable patient base for EGFR targeted drugs.

4.3　Out-Licensing Market Contribution

2024 Chinese innovative drug License-out: 98 transactions, total disclosed agreement value $59.5505 billion. The historical significance of first-year upfront payments of $3.16 billion exceeding industry R&D fundraising of $2.71 billion is that external strategic financing (out-licensing income) has become equal to primary market investment and financing as a capital source.

A License-out deal typically includes: upfront payment (paid at signing), milestone payments (phased payments linked to clinical progress), and royalties (ongoing percentage of net sales post-commercialization, typically 5–15%). The most important real cash flow is upfront payments — $3.16 billion has actually been confirmed, while milestone totals are potential only.

4.4　Consumer Structure and Channel Distribution

Hospital channel: Dominant, contributing approximately 60–70% of innovative drug sales. The DRG/DIP payment reform (disease-based payment), currently being rolled out nationally, may create structural pressure on high-cost-per-treatment cycle oncology innovative drugs.

DTP (Direct to Patient) pharmacy: High-priced innovative drug (ADC, CAR-T, targeted small molecules) direct-to-patient channel, bypassing hospital markups, providing patient support programs (compliant medication-gifting/co-payment programs).

Internet pharmacy/e-prescription: For reimbursed innovative drugs, particularly GLP-1 type drugs (type 2 diabetes medications), online penetration rate is relatively high.

4.5　R&D Investment and Profitability Structure

Hengrui Medicine 2024 R&D investment RMB 8.228 billion — domestic highest absolute value. BeiGene 2024 R&D investment approximately $1.8 billion (approximately RMB 13 billion) — R&D expense ratio exceeding 50%, typical of global Biotech high-investment model.

From the overall industry level, China Biotech's average R&D expense ratio is approximately 40–80%, with most companies remaining in the loss-making state, sustaining operations through capital market financing or License-out upfront payments.

4.6　Market Comparison with Generics

China's total pharmaceutical market scale is approximately RMB 2 trillion (2024, including generics, TCM). Generics account for approximately 75–80% of China's chemical drug market; innovative chemical drugs account for approximately 15–20%. Under continued VBP advancement, generics' average prices have been compressed to extremely low levels — multiple large categories (gefitinib, imatinib) are now priced at a few yuan per unit. The relative market share and value proportion of innovative drugs will continue to increase.

Projection: by 2030, innovative drugs (Scope 1) will account for approximately 25–30% of China's chemical drug + biologic market, up from approximately 15–18% in 2024.

4.7　Major Category Market Segmentation

Oncology innovative drugs: domestic market approximately RMB 60–70 billion (2024, Scope 1), approximately 40% of total innovative drug market. PD-1/PD-L1 monoclonals approximately RMB 20 billion; EGFR targeted drugs (osimertinib-class) approximately RMB 50–70 billion; CDK4/6 inhibitors approximately RMB 30–40 billion.

GLP-1 and metabolic drugs: approximately RMB 8–12 billion in 2024; expected approximately RMB 33 billion by 2030, the largest single source of incremental growth for metabolic innovative drugs.

Autoimmune and rare diseases: autoimmune approximately RMB 10–15 billion; rare diseases approximately RMB 3–5 billion.

4.8　Hospital vs. Outpatient Dual-Track Growth

DRG payment reform is the most important policy variable affecting hospital innovative drug usage behavior in 2023–2026. Full implementation could create structural pressure on oncology innovative drugs with high per-treatment-cycle costs.

The outpatient channel (DTP pharmacies + internet pharmacy) is rapidly growing as a critical supplement, offsetting hospital channel pressure. It is projected that the outpatient channel share of innovative drugs will increase from current approximately 25% to 35–40% by 2030.

4.9　International Market Comparison: Pricing Gap and Return Reconstruction

Keytruda's annual treatment cost in the US is approximately $170,000–180,000 per patient; in China's medical insurance formulary, annual cost is approximately RMB 30,000–50,000 (approximately $4,000–7,000) — a US-China price difference of approximately 25–40×.

In License-out negotiations, if MNCs assess that China market price ceilings are low, they may lower their total global market potential estimates for the product, compressing offered upfront and milestone totals. Balancing domestic pricing (maintaining medical insurance negotiation competitiveness) with overseas pricing (maintaining License-out negotiation leverage) is the central challenge of Chinese innovative drug companies' commercial strategies.

Rising pharmacoeconomics assessment use in medical insurance decisions: with "cost per QALY gained" (ICER) evaluations becoming increasingly referenced in insurance reimbursement decisions, innovative drug companies need to plan health economic evidence collection in early clinical development rather than retrospectively building economic models at the medical insurance application stage.

4.10　Mid-to-Long-Term Structural Outlook

Therapeutic area gravity shift: Oncology remains largest but will be approached or surpassed in growth rate by GLP-1-represented metabolic diseases and autoimmune diseases. By 2030, metabolic innovative drugs could increase market share from approximately 5% in 2024 to 15–20%.

Payment structure diversification: Commercial health insurance penetration increasing; by 2030, commercial insurance contribution to innovative drug coverage could rise from current approximately 10% to 18–22%.

Domestic substitution acceleration: Domestic innovative drug market share projected to increase from current approximately 40% to approximately 55–60% by 2030.

M&A integration acceleration: An M&A wave expected in 2026–2028 will rapidly increase industry concentration, with large-scale commercial coverage ability and pipeline breadth becoming the threshold for next-round competition.

Chapter 5　Industry Chain Analysis: CXO Ecosystem and Investment/Financing

5.1　CRO (Contract Research Organization) Ecosystem

CROs convert fixed research costs into variable costs, allowing pharma companies to outsource preclinical and clinical research tasks per project at milestone-based fees. The global CRO market is approximately $90 billion in 2024, projected $170 billion by 2030 (CAGR approximately 11%). China's overall CXO (CRO+CMO/CDMO) market is approximately RMB 130–150 billion in 2024.

Kanglong Huacheng (300759) is China's largest independent preclinical chemical CRO. WuXi AppTec (603259) is the world's largest integrated CRO/CDMO platform, with 2024 revenue approximately RMB 39 billion (approximately -8% YoY, impacted by BIOSECURE Act concerns). Tigermed (300347) is China's largest clinical CRO. Global CRO top three — IQVIA, Covance (Bayer subsidiary), PPD (Thermo Fisher subsidiary) — all have China clinical CRO operations.

5.2　CMO/CDMO Ecosystem

CDMO's business logic: after deep participation in process development, switching costs to competing CDMOs are extremely high (re-validation, regulatory re-approval), giving CDMO high "process lock-in" competitive moats.

Kelun-Biotech (002821) leads small molecule CDMO; the Paxlovid API large-scale production contract with Pfizer was its representative case. WuXi Biologics (2269 HK) is one of the world's largest biologics CDMOs, globally deployed (Shanghai/Suzhou/Wuxi/Ireland/US).

ADC specialty CDMO: ADC production is the highest-barrier CDMO sub-segment — highly toxic payload (HPAPI) processing requires specialized enclosed facilities. Currently only a handful of global CDMOs can provide commercial-scale ADC production. This scarcity is a core supply chain bottleneck.

5.3　Clinical Trial System and Regulation

China's GCP-qualified clinical trial institutions exceed 1,100. China's patient base provides unique advantages in certain indications: nasopharyngeal carcinoma incidence in China/Southeast Asia is 80% of global; HCC approximately 50% of global; gastric cancer approximately 44% of global.

China-US dual IND filings are increasingly common: estimated approximately 25–30% of domestic Biotechs now pursuing simultaneous IND filings, expected to reach 40–50% by 2030.

NMPA review capabilities have significantly improved: CDE reviewers expanded from approximately 600 (pre-2015) to over 1,200 (2024), review backlogs substantially cleared, and ICH membership compliance is gradually aligning Chinese standards with US/EU/Japan.

5.4　Investment and Financing System

China biopharmaceutical primary market financing estimated at approximately RMB 55–65 billion in 2024, significantly down from 2021 peak (over RMB 150 billion).

HK Stock Exchange Chapter 18A: Allowing unprofitable biotech companies to list (minimum market cap approximately HK$1.5 billion, with at least one core product in clinical stage). Over 70 companies listed under 18A to date, cumulative fundraising exceeding HK$200 billion.

STAR Market biopharmaceutical: Approximately 80+ listed companies, covering innovative drugs (BioAtla, MabVax, SinoCell), CRO (WuXi AppTec on STAR), and medical devices.

License-out as "fourth financing channel": 2024 upfront payments ($3.16 billion) exceeding primary market fundraising not only provides capital but also carries no equity dilution, validating the pipeline's technical quality, and initiating global collaboration networks.

5.5　Industry Chain Cost Structure and Profitability Model

Drug R&D cost breakdown (industry average): Target validation + preclinical: approximately $50–100M (3–5 years); Phase 1 clinical: approximately $30–80M (1–2 years); Phase 2 clinical: approximately $100–300M (2–4 years); Phase 3 clinical: approximately $300M–$1B (3–5 years); NDA filing and pre-launch preparation: approximately $10–50M. Full-chain success requires approximately $500M–$1.5B, but considering failure probabilities at each stage, the true capitalized average cost of an approved drug is approximately $1 billion+.

China's CRO ecosystem significantly reduces costs through Phase 2: estimated domestic Biotech early R&D costs are approximately 30–50% of equivalent US studies — this "cost-performance advantage" is the core source of Chinese innovative drugs' global competitiveness.

5.6　Industry Chain Competition Trends

Global CRO integration: IQVIA (Quintiles + IMS merger), LabCorp acquiring Covance, PPD merging into Thermo Fisher — these integrations have formed comprehensive data service + CRO platforms. Domestically, Tigermed has expanded through acquisitions; WuXi AppTec has built the most integrated "CRDMO" platform.

BIOSECURE Act's restructuring of CXO landscape: if enacted, global pharma companies will assess diversification of CXO suppliers beyond China. Samsung Biologics (Korea), Lonza (Switzerland), Catalent (US), and AGC Biologics (Japan) will gain more US pharma outsourcing orders.

China CDMO technology upgrade path: ADC CDMO capacity build-out (HPAPI enclosed operation systems); Cell Gene Therapy (CGT) CDMO (personalized CAR-T production requiring sterile single-batch capabilities); Continuous Flow Chemistry for small molecule CDMO.

Chapter 6　Competitive Landscape and Major Enterprises

6.1　Overall Competitive Landscape

China's innovative drug competitive landscape has undergone structural transformation from "land rush" to "leaders consolidate" over the past five years. In 2018–2021, capital flooded in and hundreds of Biotechs simultaneously targeted similar indications. After 2022, with financing winter, deeper medical insurance negotiation, and me-too commercialization challenges, differentiation accelerated.

China's innovative drug CR3 (top three combined market share) is approximately 20–25%, CR10 approximately 40–45% — significantly lower than the global innovative drug market where top ten MNCs account for over 40%. Three typical enterprise models coexist: large traditional pharma transformation (Hengrui), global Biotech (BeiGene), and domestic volume-growth Biotech (Innovent, Akeso).

6.2　Hengrui Medicine (600276) — The Most Deeply Transformed Legacy Pharma

FY2024 financials: Innovative drug sales RMB 13.892 billion (+30.6%), net profit RMB 6.337 billion (+47.3%), R&D investment RMB 8.228 billion.

FY2025 financials (annual report released): Total revenue RMB 31.629 billion (+13.0%); innovative drug revenue RMB 16.342 billion (+26.1%), reaching 58.3% of total drug sales; net profit RMB 7.711 billion (+21.7%); R&D investment RMB 8.724 billion (27.6% of revenue, domestic record in absolute value). Non-tumor products revenue RMB 3.102 billion (+73.4%), improving structure. 2026 target: innovative drug revenue growth >30%. Out-licensing revenue FY2025: RMB 3.392 billion (+25.6%). (Source: Company FY2025 Annual Report, March 2026)

License-out progress: 2024 major transactions: Merck KGaA's €160M upfront for SHR-1701 (TGF-β/PD-L1 bifunctional fusion); Kailera Therapeutics' $100M upfront (total $6 billion) for GLP-1 product portfolio.

Core pipeline: GLP-1 portfolio (authorized to Hercules/Kailera, $6 billion total); PD-L1 adebrelimab (SHR-1316); ADC SHR-A1811 (HER2 ADC, Phase 2); CDK4/6 inhibitor Haishenpu (SHR6390, approved in China for breast cancer); JAK1 inhibitor SHR0302 (autoimmune).

Competitive advantage: Largest BD team and global licensing negotiation experience among domestic pharma. Challenges: Generics revenue continuing to decline under VBP pressure; uncertainty whether GLP-1 pipeline will stand out in international clinical competition.

6.3　BeiGene (688235/BGNE/6160 HK) — Most Globally Oriented Chinese Biotech

FY2024 financials: Total revenue $3.8 billion (+55%), net loss RMB 4.978 billion (narrowed from RMB 6.7 billion in 2023).

FY2025 financials (annual report released): Total revenue RMB 38.225 billion (+40.5%); first-ever GAAP full-year profit since IPO (net profit RMB 1.461 billion, reversing FY2024 loss of RMB 4.978 billion); operating cash flow RMB 13.713 billion (swung from -RMB 1.259B to +RMB 13.713B YoY); product revenue RMB 37.770 billion (+39.9%). 2026 revenue guidance approximately RMB 43 billion (~$6 billion). (Source: Company FY2025 Annual Report, April 2026)

Zanubrutinib (百悦泽): FY2025 global sales approximately RMB 28.067 billion (~$3.85 billion) (+48.8%); US approximately RMB 20.2 billion (+45.5%), Europe RMB 4.265 billion (+66.4%), China RMB 2.472 billion (+33.1%); approved in 75+ countries globally. Zanubrutinib FY2025 surpassed ibrutinib to become the #1 BTK inhibitor worldwide. Head-to-head ALPINE Phase 3 (CLL) superiority in PFS over ibrutinib remains the defining best-in-class clinical proof.

Other pipeline: TIGIT monoclonal ociperlimab (BGB-A1217) Phase 3 data in SCLC showing positive signal; multiple PROTAC candidates in early clinical; inhaled IL-5 monoclonal in Phase 2.

6.4　Innovent Biologics (1801 HK) — From PD-1 Pioneer to Diversified Portfolio

FY2024 financials: Total revenue RMB 9.42 billion (+51.8%), loss narrowed to RMB 95 million.

FY2025 financials (annual report released): First-ever GAAP annual profit (GAAP net profit RMB 810 million; Non-GAAP net profit RMB 1.72 billion), driven by mazdutide commercialization launch and sintilimab multi-indication ramp. (Source: Innovent Biologics FY2025 Annual Report, 2026)

Sintilimab (达伯舒, PD-1): Commercial baseline across multiple indications. Mazdutide (IBI362, 信尔美, GLP-1/GCG dual agonist): NMPA-approved June 2025 for adult obesity/overweight (long-term weight management) and September 2025 for type 2 diabetes — first domestic GLP-1 product to receive dual approval for both indications simultaneously (Source: NMPA, 2025). Licensed to Eli Lilly ($250M upfront, total up to $1.91 billion). IBI363 (PD-1/IL-2α-bias bispecific): First-in-class pipeline, multiple Phase 1/2 ongoing.

6.5　Junshi Biosciences (688180) — Toripalimab's FDA Breakthrough

Junshi's non-replaceable milestone: toripalimab (拓益) was the first PD-1 monoclonal antibody developed by a Chinese domestic Biotech to receive FDA approval (October 2023, nasopharyngeal carcinoma indication).

FY2024 financials: Revenue RMB 1.948 billion (+29.67%), toripalimab sales RMB 1.501 billion (+66%).

FY2025 financials: Revenue RMB 2.498 billion (+28.2%), toripalimab domestic sales RMB 2.068 billion (+37.7%); net loss RMB 875 million (narrowed by RMB 316 million YoY). (Source: Company FY2025 Annual Report, March 2026)

Nasopharyngeal carcinoma is specifically prevalent in Chinese/Southeast Asian populations; this epidemiological characteristic enabled FDA approval based on relatively smaller patient data from predominantly Asian patients — toripalimab is a representative case of Chinese clinical data being directly accepted by FDA.

Pipeline limitations: Relatively shallow beyond toripalimab; major pipeline includes BTLA monoclonal (JS004) combined PD-1 regimens, GLP-1 candidates, all in early stage.

6.6　Akeso (9926 HK) — Bispecific Pioneer with Financial Volatility

FY2024 financials: Revenue RMB 2.124 billion (-53.1%, base effect from Sanofi upfront in 2023); commercial sales RMB 2.044 billion (+25.3%); net loss RMB 515 million.

FY2025 H1 (interim): Total revenue RMB 1.412 billion (+37.8%), commercial sales RMB 1.402 billion (+49.2%); ivonescimab and cadonilimab both added to 2025 NRDL with new indications (ivonescimab 1L NSCLC PD-L1+ and cadonilimab 1L cervical cancer full population), driving a sales ramp. Full-year FY2025 data pending; trajectory strongly accelerating. (Source: Akeso FY2025 H1 Interim Report, August 2025)

Cadonilimab (开坦尼): Approved for cervical cancer, nasopharyngeal cancer; 2025 NRDL-included first-line cervical cancer (all comers). Ivonescimab (依沃西): HARMONi global Phase 3 updated data presented at WCLC 2025 — met the primary endpoint of PFS; Summit's HARMONi-3 (1L NSCLC + chemo) and HARMONi-7 (1L PD-L1 high) are ongoing; new Phase 3s in colorectal cancer and pancreatic cancer also initiated. (Source: Akeso corporate website, WCLC 2025)

6.7　Legend Biotech (LEGN) — Global CAR-T Commercialization Blueprint

Legend Biotech's ciltacabtagene autoleucel (西达基奥仑赛, Carvykti) is the most successful example of a Chinese Biotech in global CAR-T commercialization.

FY2024 commercial data: Carvykti global sales approximately $963 million (J&J financials), with FDA 2-line expansion approved.

FY2025 commercial data (first three quarters disclosed): Q1 $369M (+135% YoY), Q2 $439M, Q3 $524M (quarterly record); cumulative first three quarters $1.332 billion; full year estimated $1.8–2.0 billion (+85%+ YoY), approaching or exceeding "blockbuster" threshold. Legend Biotech announced $150M capacity expansion investment. (Source: Legend Biotech Q3 2025 results, November 2025)

Legend's J&J partnership model: Legend contributed Chinese domestic R&D and preclinical technology; J&J provided global clinical development capability, regulatory expertise, and commercialization network.

6.8　BioAtla (688506) and Kelun-Biotech (6990 HK) — ADC Sector Duo

BioAtla: The 2024 standout Chinese innovative drug out-licensing case is BL-B01D1. This EGFR×HER3 bispecific ADC uses topoisomerase I inhibitor payload + site-specific coupling Linker technology platform, with potential cooperative killing of EGFR/HER3 co-expressing tumors (NSCLC/breast cancer).

BMS paid $800 million upfront (total $8.4 billion including milestones), record for a Chinese drug single upfront payment. As of mid-2025, BioAtla has initiated 9 Phase 3 registration studies for BL-B01D1 in China (5 indications with Breakthrough Therapy designation by CDE); BMS initiated a BL-B01D1 Phase 2/3 registration study for advanced TNBC in the US in April 2025 (targeting 560 patients), and a new IND for combination therapy in solid tumors received FDA clearance. Early bladder cancer ORR of 75% supports the global registration trial push. ASCO 2025 featured two important clinical readouts. (Source: CDE/NMPA, BMS announcement, ASCO 2025)

Kelun-Biotech: Platform-level ADC company. Three rounds of collaboration with MSD (2022–2024), cumulative $11.821 billion. Lead asset SKB264 (MK-2870, TROP2 ADC) has received three FDA Breakthrough Therapy Designations — for TNBC, EGFR-mutated NSCLC after TKI failure, and HR+/HER2- breast cancer. MSD has registered 13 global Phase 3 studies on ClinicalTrials.gov targeting 4,380+ patients across tumor indications, the broadest global clinical footprint of any single Chinese ADC asset.

6.9　RemeGen (688331/9995 HK) and Zymeworks (9688 HK)

RemeGen: One of few domestic companies with commercialized products in both ADC and autoimmune lines. Disitamab vedotin (RC48, HER2 ADC, first domestically developed ADC approved in China) approved for gastric cancer/GEJ adenocarcinoma and urothelial carcinoma. Telitacicept (BLyS/APRIL dual target, RC18) approved for SLE.

Zai Lab (再鼎医药): "License-in + self-development" hybrid model. 2024 sale of niraparib (PARP inhibitor) global rights to GSK — Zai Lab's important milestone transforming from "importer" to "licensor."

6.10　Other Notable Enterprises

BeiGene (300558): Icotinib (国内首个第一代EGFR inhibitor, approved 2011), ensartinib (ALK inhibitor).

SinoCell Technology (688520): Recombinant human coagulation factor VIII (SCT800, hemophilia A) — China's first domestic recombinant protein drug for hemophilia A, rare disease self-development benchmark.

Henlius (2696 HK): Trastuzumab biosimilar (HanliZhu) approved in multiple countries globally, Chinese biosimilar out-licensing front-runner.

Hua Medicine (2552 HK): Dorzagliatin (first-in-class glucokinase activator, GKA, type 2 diabetes, approved in China 2022) — one of the few first-in-class domestic innovative drugs in the type 2 diabetes field.

6.11　Commercialization Capability Building

In-hospital promotion: Hospital-channel commercialization requires specialized MSL teams. Hengrui has approximately 2,000–3,000 front-line sales forces (including innovative drug promotion teams), Innovent approximately 800–1,000, BeiGene (domestic) approximately 500–700.

Digital commercialization tools: Pharma companies access precision patient identification data through hospital HIS/EMR de-identified collaborations or third-party medical data platforms (IQVIA, Veeva). Internet medical platforms (JD Health, AliHealth, Haodafu) provide online physician education and patient service channels.

Patient assistance programs and commercial insurance collaboration: Domestic major Biotech patient assistance plans provide compliant drug donation during pre-reimbursement waiting periods. Urban custom commercial medical insurance (Huimin Bao) participating over 100 million persons in 2024, with some innovative drugs included in coverage.

6.12　Competitive Landscape Outlook

Concentration increase: Financing winter accelerates natural elimination of companies with weak capital and insufficient pipeline differentiation. CR10 expected to rise from current approximately 40% to 50%+ over the next five years.

Differentiation competition intensification: ADC platform, bispecific technology, next-generation GLP-1, and first-in-class targets are the four key differentiation dimensions in 2026–2030. Companies with these capabilities will receive higher capital market valuations and more MNC partnership opportunities.

6.13　Innovative Drug ESG and Sustainable Development

Patient accessibility: The social dimension (S) of ESG increasingly scrutinizes patient accessibility. Medical insurance negotiation compliance and patient assistance program coverage depth are important ESG assessment dimensions for Chinese innovative drug companies.

Environmental compliance: Large-scale biological fermentation production and chemical synthesis (particularly ADC high-toxicity payload handling) create environmental disposal requirements. WuXi AppTec's Shanghai/Suzhou facilities have achieved ISO 14001 certification; ADC specialty CDMO toxic payload waste disposal must comply with hazardous waste management regulations.

6.14　2024 Innovative Drug Industry Annual Key Event Review

Largest License-out transactions: Hengrui's GLP-1 portfolio licensing to US Hercules ($6 billion total); BioAtla BL-B01D1 to BMS (actual $800M upfront received, total $8.4 billion); Innovent mazdutide to Lilly (total up to $1.91 billion).

Important clinical milestones: BeiGene zanubrutinib global sales breakthrough $2.6 billion (+105%), first Chinese pharma self-developed product exceeding $2.5 billion in global annual sales; Legend Biotech Carvykti FDA 2-line expansion; Akeso ivonescimab NMPA approval for NSCLC first-line.

Major policy milestones: Innovative drugs included in State Council Government Work Report for first time; State Council issued "Full-chain Support for Innovative Drug Development Implementation Plan"; NMPA approved 90 new drugs (14 Breakthrough Therapy designations); 9th medical insurance negotiation completed (avg. -63.5%, success rate ~73.5%).

6.15　2025 Innovative Drug Industry Annual Key Event Review

Historic License-out breakthrough: 2025 full-year total agreement value approximately $135.6 billion (157 transactions, +2.5× YoY); China surpassed the US to represent ~49% of global out-licensing deal value. Deals expanded beyond ADC/GLP-1 to include bispecifics, nucleic acid drugs, and autoimmune across all tracks. (Source: Pharmcube, January 2026)

Major company financial milestones: BeiGene FY2025 first-ever GAAP full-year profit (net RMB 1.461 billion), zanubrutinib surpassed ibrutinib as global #1 BTK inhibitor; Innovent FY2025 first-ever GAAP annual profit (net RMB 810 million); Hengrui FY2025 all-time high revenue/profit (revenue RMB 31.629 billion, net profit RMB 7.711 billion).

Key clinical/commercial milestones: Innovent mazdutide approved June 2025 (obesity/overweight) and September 2025 (T2D) — first domestic dual-indication GLP-1; Akeso ivonescimab HARMONi Phase 3 met PFS primary endpoint (WCLC 2025); Legend Biotech Carvykti FY2025 Q1–Q3 sales $1.332 billion, full year ~$1.8–2.0 billion; BioAtla BL-B01D1 global Phase 3 underway in China and US, BMS US II/III enrollment commenced.

Major policy milestones: NMPA 2025 approved 120 new drugs (historic record, excluding TCM), domestic products first exceeded 50% (63 drugs); 2025 NRDL negotiation: 114 new drugs added, 88% success rate (7-year high), 50 Class 1 innovative drugs included; NMPA Document [2025] No. 86 issued October 2025 to optimize innovative drug clinical trial review and accelerate IND approvals; semaglutide and tirzepatide prices cut by ~50%+ in China by year-end, GLP-1 price competition intensified. (Source: NMPA, NHSA, CDE)

Chapter 7　Mid-Stream Industrial Clusters and Factory Identification

7.1　China Innovative Drug Industry Map Overview

China's innovative drug geographical layout has evolved from dispersed to concentrated over thirty years, forming a "one core, multiple poles" pattern with the Yangtze River Delta as core, Beijing-Tianjin-Hebei as secondary, and Pearl River Delta rapidly rising.

Five core clusters: Shanghai Zhangjiang (Shanghai Pudong), Suzhou BioBAY (Suzhou Industrial Park), Beijing Zhongguancun Life Science Park, Guangzhou International Bio-Island and Guangzhou Knowledge City, and Chengdu Tianfu New Area.

Second-tier clusters: Wuhan Optics Valley Biocity, Hangzhou Qiantang New Area, Nanjing Jiangbei New Area, Shenzhen Pingshan National Bioindustry Base, and Jinan International Medical Science Center.

Cluster formation logic: innovative drug R&D requires high-density talent pools (graduates from top universities and research institutes), accessible early-risk capital (VC/PE ecosystem), supporting CRO/CDMO service systems (reducing R&D costs), and large tertiary hospitals (clinical trial resources).

7.2　Shanghai Zhangjiang — China's Premier Biopharmaceutical Pole

Zhangjiang High-Tech Park clusters over 1,400+ biopharmaceutical innovation entities; 8 of the global pharmaceutical top 10 have established R&D centers here; approximately 1/3 of China's pharmaceutical industry top 100 companies have R&D departments in Zhangjiang.

Zhangjiang's "flagship effect": Lilly China R&D Center (established 1993), Roche China R&D Center, and AstraZeneca China R&D Center have long attracted scientific talent from overseas, creating a positive feedback loop of knowledge spillover and talent mobility.

Zhangjiang's layout characteristics: R&D and early clinical highly concentrated; mid-to-late clinical and large-scale commercial manufacturing more transferred outward (CDMOs in Suzhou, Hangzhou). Major universities (Fudan, Jiao Tong University, Tongji University Medical School) provide continuous academic transformation momentum.

7.3　Suzhou BioBAY — Highest Biotech Incubation Density in China

BioBAY core clusters over 650+ innovative drug and medical device companies; the full Suzhou Industrial Park clusters over 2,000+ biopharmaceutical enterprises; 2023 biopharmaceutical output exceeded RMB 150 billion; approximately 35,000 high-level science and technology talent.

BioBAY's "open innovation" model: standardized, flexibly configured laboratory space; professional entrepreneurship support platform (legal/financial/IP services); close collaboration with Suzhou Industrial Park management committee for streamlined approvals.

BioBAY representative company: Innovent Biologics (headquartered in Suzhou), 2024 revenue RMB 9.42 billion, approaching break-even from Suzhou incubation to global operation — BioBAY's iconic growth sample.

Suzhou's synergy with Shanghai creates a "pharmaceutical corridor" — Zhangjiang (discovery and early development) — BioBAY (incubation and preclinical/Phase 1) — Nanjing/Zhenjiang (manufacturing) — forming a complete innovative drug R&D-to-manufacturing integrated belt along the Shanghai-Nanjing corridor.

7.4　Beijing Zhongguancun Life Science Park — Academic Translation Center

Beijing's core advantage is academic resource density: Peking University, Tsinghua University, CAMS/Peking Union Medical College, and CAS Institute of Molecular Cell Science. The park clusters over 300+ biopharmaceutical enterprises.

BeiGene has major research center in Beijing (molecular design and drug chemistry departments); Nuance Pharma (688428/9969 HK, BTK/JAK inhibitors) has R&D headquarters in Beijing.

Beijing's relative disadvantage in innovative drug industrialization: manufacturing resources not as rich as Yangtze River Delta; large-scale CDMO production capacity mainly concentrated in Suzhou/Wuxi/Shanghai. However, its academic research depth advantage remains nationally strongest in target discovery and basic research translation.

7.5　Guangzhou Bio-Island and Guangzhou Knowledge City

Guangzhou's biopharmaceutical industry scale exceeded RMB 80 billion in 2024, ranking in the national top five. BeiGene has production base in Guangzhou; Nuance Pharma has partial R&D layout; Lvye Pharmaceutical and other companies are present.

Shenzhen Pingshan National Bioindustry Base (BioRAF): Companies including NOVATEK Microelectronics and Mindray Medical have deployed. Shenzhen's advantages: proximity to Hong Kong capital markets (HK IPO convenience), export-oriented manufacturing base (hardware supply chain), highly open business environment. In medtech + biotech combined innovation, Shenzhen holds relative comparative advantages.

GBA's special innovative drug value extends to: Hong Kong's Northern Metropolis (including Lok Ma Chau Loop) planning potentially enabling dual licensing recognition, unlocking a path for simultaneous NMPA and Hong Kong/EU/FDA registration.

7.6　Supply Chain Ecosystem and Factory Identification

Innovative drug supply chains are significantly more complex than general manufacturing. A single innovative drug's midstream supply chain involves: API suppliers, key starting material (KSM) suppliers, finished drug CMO (tablets/injections), ADC conjugation specialty CDMO (containing toxic payload processing permits), analytical testing CRO (QC/QA), and cold chain logistics providers (biologics -2°C–8°C refrigeration or -80°C ultra-low temperature).

ADC supply chain specifics: ADC drug production requires maintaining simultaneously: mAb drug substance manufacturing lines (large-scale cell culture, sterile fill), highly active cytotoxic payload synthesis lines (HPAPI permit, enclosed operation), precision conjugation facilities (conjugation reactors, real-time DAR monitoring analytical instruments), and final product sterile dispensing and ultra-low temperature storage. These four segments' factories are typically not co-located, and each requires additional regulatory permits and quality system validation — the source of ADC supply chain scarcity.

Clinical-stage CDMO niche: Unlike large commercial CDMOs serving marketed products, small-to-mid-sized CDMOs focused on clinical stages handle Phase 2–3 clinical trial drug substance/formulation in small quantities (gram to hundred kilogram scale), emphasizing flexibility and process development rather than ton-scale capability.

In identifying China's truly operating CDMO/CMO factories and clinical outsourcing service providers, traditional business registration databases can retrieve registration information but cannot distinguish genuinely operating factories from shell companies or investment holding companies. Tianxia Gongchang (www.tianxiagongchang.com) has collected data on approximately 4.8 million genuinely operating factories, covering API manufacturers, formulation CMOs, ADC conjugation mid-sized factories, and other innovative drug upstream manufacturing partners. Its "genuinely operating factory" verification logic — based on actual production status rather than mere business registration — provides a unique data perspective for innovative drug supply chain supplier due diligence and partner factory screening, with distinctive data advantages on the question of "who is the genuinely operating upstream innovative drug support factory."

7.7　Industrial Cluster Competitive Landscape Evolution

Yangtze River Delta's leading advantage: Shanghai/Suzhou/Nanjing synergy forms a complete R&D-to-manufacturing-to-commercialization closed loop. Talent reserves, capital density, and policy pioneering constitute non-replicable integrated advantages.

Pearl River Delta's late-mover rise: Guangzhou biopharmaceutical 2024 exceeding RMB 80 billion has made it a co-innovation drug R&D dual core alongside the Yangtze River Delta. Hong Kong capital markets (HK Chapter 18A) provide special financing advantages.

Beijing's academic translation comparative advantage: Highest-density target discovery and basic research translation nationally, but relatively weak in large-scale commercial manufacturing — a "strong R&D, weak manufacturing" pattern.

Inland (Chengdu/Wuhan) differentiated positioning: Chengdu Tianfu New Area biopharmaceutical approximately RMB 50 billion scale (2024); Wuhan Optics Valley Biocity with Huazhong University of Science and Technology Tongji Medical College and Wuhan University. Inland clusters' core competitiveness is relatively lower operating costs.

7.8　API Industrial Clusters and Supporting Factory Ecosystem

China is the world's largest API manufacturer, supplying approximately 40% of global generics and biosimilar APIs. Key API industrial clusters: Zhejiang Taizhou (penicillin/cephalosporin APIs), Zhejiang Shaoxing (chemical APIs), Shandong Zibo/Weifang (vitamins/steroid hormones), Hebei Shijiazhuang/Baoding (antibiotics and chemical APIs).

For innovative drugs, the key is not commodity APIs but Novel APIs — proprietary active ingredients protected by innovation drug companies. These molecules are not accessible to generic API factories.

Excipients and formulation support: High-purity pharmaceutical excipients (mRNA preparation ionizable lipids, ADC linker precursors) are primarily supplied by European/US chemical companies (Lipoid, Merck/Sigma-Aldrich, Evonik). Domestic companies are building substitution capabilities but need 3–5 years to reach commercial-scale, high-quality supply.

Sterile fill-finish capacity: Innovative drug final products require sterile filling under ISO Class 5 conditions. ADC products additionally require closed-system filling (RABS/isolators) — specialized equipment primarily supplied by European manufacturers (Bosch Packaging, Groninger, IMA).

7.9　Global Innovative Drug Supply Chain Migration to China

Over the past five years, certain manufacturing segments of the global innovative drug supply chain have accelerated migration to China, driven by cost and speed: CDMO order Chinafication (US and European pharma companies increasingly outsourcing clinical-stage API synthesis and early clinical formulation to China), large-molecule CDMO capacity build-out (WuXi Biologics multi-site large-scale CHO cell culture facilities), and quality compliance system internationalization (more domestic CDMOs passing FDA/EMA audits).

Projected by 2030, China CDMOs' share of global clinical-stage API/biologic outsourcing will rise from approximately 20–25% in 2024 to 30–35%, becoming an indispensable core node in the global biopharmaceutical manufacturing system.

7.10　Cluster Talent Ecosystem and R&D Translation Mechanisms

Academic and research institute output: Top Chinese universities and research institutes are achieving quantity-quality dual improvement in biopharmaceutical output. CAS Institute of Molecular Cell Science, NIBS (Beijing Institute of Life Sciences), and similar institutions are becoming science incubators for the next generation of Biotech founders.

Overseas returnee scientists and industry feedback: Returning overseas Chinese scientists from MNC R&D centers (Pfizer/Merck/Lilly/Novartis/Roche/Genentech) and top US universities (Harvard/Stanford/MIT/UCSF) are driving China's second wave of Biotech entrepreneurship (2021–2025). Local government talent introduction programs (Shanghai's "Haiju Yingcai," Suzhou's "Gusu Entrepreneurship Innovation Leadership Talent Program") have accelerated this return.

University-enterprise cooperation: Suzhou Industrial Park (BioBAY location) has established the most systematized university-enterprise biopharmaceutical innovation cooperation system: joint research institutes with China Pharmaceutical University, Soochow University, and Nanjing University of Chinese Medicine, providing full-chain support from "idea validation" to "angel round financing."

Chapter 8　Sub-Track Special Topics

8.1　PD-1/PD-L1 Immune Checkpoint Inhibitors — The Same-Ization Battle

8.1.1　Global and China PD-1 Landscape

PD-1/PD-L1 pathway blockade has become the standard of care for multiple solid tumors and blood cancers. Globally, Merck's Keytruda is the undisputed commercial dominant, approximately $25 billion in 2024 annual sales; BMS's Opdivo approximately $10 billion annually.

In China, 10 PD-1/PD-L1 monoclonals have been approved as of end-2024, with 4 domestic (sintilimab, camrelizumab, toripalimab, tislelizumab) and 6 imported.

Product	Company	1st Approval	Est. 2024 Sales	Key Indications (China)
Sintilimab (达伯舒)	Innovent	2018	~RMB 30–35B	Lung/liver/gastric/lymphoma
Camrelizumab	Hengrui	2019	~RMB 20–25B (cumulative >RMB 200B)	Lung/liver/esophageal/Hodgkin
Toripalimab (拓益)	Junshi	2018	~RMB 15B	NPC/urothelial/gastric; US FDA NPC approved
Tislelizumab (百泽安)	BeiGene	2019	~RMB 25–30B	Lung/liver/biliary/gastric/lymphoma

Bispecifics' structural disruption of PD-1 monotherapy: Cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF) represent next-generation immunotherapy products' substitution trend for PD-1 monotherapy. Bispecifics replace two-drug combinations with a single injection, showing efficacy advantages over PD-1 monotherapy in some indications.

8.1.2　PD-1 Track Commercialization Challenges

PD-1 monoclonals in China face ongoing price pressure from medical insurance negotiation. Domestic PD-1 response strategies include: expanding indication coverage, combination therapy development (PD-1+chemo/PD-1+VEGFR inhibitors), and overseas market development.

8.2　ADC — China's Hottest Out-Licensing Track

Global ADC market approximately $10–12 billion (2024), projected $30–35 billion by 2030, CAGR approximately 16–18%. Technology iteration: first-generation (random conjugation, non-uniform DAR 3–5, Kadcyla/early products) → second-generation (site-specific, DAR 4 uniform) → third-generation (site-specific + novel Linker + novel payload, DAR precisely 4–8). Enhertu (AstraZeneca/Daiichi Sankyo) exemplifies third-generation ADC with "bystander effect" mechanism in HER2-low indication breakthrough.

Chinese ADC out-licensing: 25 transactions, nearly $40 billion cumulative (2021–2024), the largest out-licensing volume by technology category.

BioAtla BL-B01D1: EGFR×HER3 bispecific ADC, BMS $800M upfront (total $8.4B), Phase 3 ongoing; potential same-category-first for EGFR/HER3 co-expressing tumors.

Kelun-Biotech: Three rounds with MSD, cumulative $11.821B, covering multiple ADC candidates; platform-level licensing model.

RemeGen RC48: China's first self-developed approved ADC (HER2, gastric/GEJ and urothelial cancer); demonstrates complete path from R&D to market.

ADC Phase 3 failure rate approximately 65% — key risk factor. HPAPI production facility scarcity is a critical supply bottleneck.

8.3　GLP-1 Drugs — China's Position in the World's Hottest Track

Global GLP-1 market approximately $50–60 billion (2024), Lilly tirzepatide $17.6B and Novo Nordisk semaglutide $20B+.

Domestic GLP-1 market by 2030: approximately RMB 33 billion (type 2 diabetes RMB 15.5B + overweight/obesity RMB 17.3B).

Key domestic players: Innovent mazdutide (GLP-1/GCG, NDA submitted, licensed to Lilly $250M upfront); Hengrui 3-product portfolio licensed to Kailera ($6B total); Sino Biopharm liraglutide biosimilar (approved 2023 in China for weight management). Key variables: insurance coverage timeline for weight loss indication (expected 2026–2028 window); next-generation multi-target molecules' clinical validation.

8.4　Bispecific Antibodies — Next-Generation Immune Treatment Engine

Bispecific antibody technology challenge: ensuring two different heavy chains correctly pair during production, rather than forming inactive homodimers. Main platform formats: Knob-into-hole (KiH, most widely used heterodimerization strategy), BiTE (tandem scFv, short half-life), IgG-like formats (CrossMab etc., long half-life, subcutaneous injection possible).

Akeso's ivonescimab (PD-1/VEGF bispecific): simultaneous blockade of immune checkpoint and tumor angiogenesis, theoretically superior to PD-1 monotherapy + bevacizumab combination; Sanofi $5B upfront + total up to $7.569B global licensing.

Cadonilimab (PD-1/CTLA-4, global first IgG4 subtype bispecific of this class). Roche Hemlibra (emicizumab, FVIII-mimetic bispecific, hemophilia A, approximately $4B annual sales) — most successful bispecific commercialization outside oncology.

8.5　CAR-T Cell Therapy — The Medical Insurance Dilemma of Million-Yuan Pricing

Three domestic approved CAR-T products (through 2024):

Product	Target	Company	Approval	Indication
Relma-cel (倍诺达)	CD19	WuXi Junuo	2021	R/R LBCL
Axicabtagene ciloleucel (奕凯达)	CD19	Fosun Kite	2021	R/R LBCL
Ciltacabtagene autoleucel (傅曹西)	BCMA	Legend-J&J	2023	Multiple myeloma

Legend Carvykti global sales approximately $500–600 million (2024), first BCMA CAR-T, rapidly climbing globally. CAR-T pricing RMB 1–1.2 million/dose remains far above medical insurance capacity; only partially covered by city-customized commercial insurance (Huimin Bao).

Next-gen: Off-the-shelf (allogeneic donor) CAR-T is the technical path to solve high cost; dual-target CAR-T (CD19+CD22/CD19+CD38) for lower antigen escape recurrence risk.

8.6　Sub-Track Comprehensive Comparison

Track	Global Market (2024)	China Market (est. 2024)	Tech Barriers	Key Domestic Players	Out-licensing Activity
PD-1/PD-L1	~$35B	~RMB 10B	Medium	Hengrui/Innovent/Junshi/BeiGene	Medium
ADC	~$10–12B	~RMB 5B	High	BioAtla/Kelun/RemeGen	Extremely high
GLP-1	~$50–60B	~RMB 3B (early)	Medium-high	Innovent/Hengrui/SinoPharma	High
Bispecific	~$5–6B	~RMB 2B	High	Akeso/Innovent	High
CAR-T	~$4–5B	~RMB 1.5B	Extremely high	Legend/Fosun Kite/WuXi Junuo	High
CDK4/6	~$6B	~RMB 1.5B	Medium	Hengrui etc.	Low
mRNA	~$20B (vaccines)	~RMB 2B	High	CanSino/others	Low (early)

8.7　Autoimmune Disease and Rare Diseases

Autoimmune disease global market approximately $160 billion. AbbVie Skyrizi/Rinvoq rapid growth validates IL-23p19 and JAK1 commercial potential. Domestic progress: RemeGen telitacicept (approved SLE in China); Innovent IBI112 (IL-23p19 inhibitor, psoriasis NDA submitted); JAK1 inhibitors from Hengrui/Junshi in Phase 2/3.

Rare disease policy: dedicated expedited review channel (Priority Review) and conditional approval mechanism. SinoCell Technology's recombinant human coagulation factor VIII ended complete reliance on imported clotting concentrates for Chinese hemophilia A patients.

8.8　Tumor Immunotherapy — From Monotherapy to Combination Therapy

Tumor immunotherapy's clinical landscape has shifted from the PD-1 monotherapy era (2016–2021) to the multi-drug combination era (2022–present). PD-1 monotherapy typically achieves only 15–30% ORR in unselected patients; combination therapy (chemo/anti-angiogenic/bispecifics/ADC) is needed to expand the benefiting population.

China-specific tumor research advantages: Nasopharyngeal carcinoma incidence in South China/Southeast Asia approximately 20–30/100,000 (vs. Western 0.5/100,000); HCC approximately 50% of global cases (HBV-related); ESCC China incidence globally highest; gastric cancer approximately 44% of global cases. These China-endemic high-incidence cancers provide unique domestic clinical research enrollment speed and data quality advantages.

8.9　Non-Oncology Innovative Drug Opportunities

Cardiovascular innovative drugs: Chinese cardiovascular patients approximately 330 million; PCSK9 inhibitor (Inclisiran siRNA vs. evolocumab/alirocumab monoclonal approaches), ARNI biosimilars facing competitive saturation; true incremental opportunity in H-type hypertension-related stroke (China-specific high-risk population).

Metabolic disease diversification: NASH (first approved therapy Resmetirom from Madrigal, FDA 2024 approval) opening commercial precedent; multiple Chinese Biotechs targeting NASH, some combining with GLP-1. Hyperuricemia/gout: approximately 120 million high-uric-acid patients in China; domestic innovative small molecules (URAT1 inhibitors) rapidly emerging.

8.10　Sub-Track Investment Strategy Differentiation Framework

Short-term (1–2 years) most certain direction: Companies with commercial volume-growth products (Hengrui innovative drugs RMB 13.892B growing, BeiGene zanubrutinib $2.6B +105%, Innovent GLP-1 expected approval and commercialization) — approaching cash flow positive or break-even, relatively stable valuations.

Medium-term (2–4 years) key bets: Companies awaiting critical Phase 3 data readouts — BioAtla BL-B01D1, Akeso ivonescimab global Phase 3 data, Innovent mazdutide (post-approval commercialization ramp). High elasticity depending on clinical data meeting expectations.

Long-term (4–6 years) layout direction: First-in-class early pipelines and AI pharma platforms — longest time horizons, highest uncertainty, but highest potential returns. Suitable for professional institutional investors with long-term holding capacity.

Chapter 9　Technology Evolution Trends

9.1　ADC Conjugation Technology Generational Iteration

ADC technology has one of the clearest generational iteration paths in biopharmaceuticals over the past decade.

First-generation ADC: Random conjugation (attaching payload randomly to antibody lysine residues or free thiols), resulting in non-uniform DAR (range 0–8, average 3–4). Kadcyla is the most commercially successful first-generation ADC ($2–2.5B annual sales), but side effects (thrombocytopenia etc.) limit broad clinical use.

Second-generation ADC: "Site-specific conjugation" — genetically engineered specific non-natural amino acids, cysteine mutations, or THIOMAB technology precisely attaches payload at defined antibody positions, achieving uniform DAR 4 product specification, significantly improving uniformity and therapeutic window.

Third-generation ADC (Enhertu as representative): Three technical advances: (1) hydrophilic cleavable Linker (Gly4Pro hexapeptide + cleavable amide bond) — extremely stable in plasma, only cleaving in tumor cell lysosomal environment; (2) topoisomerase I inhibitor Dxd (deruxtecan) payload — stronger bystander effect than MMAE/DM1, penetrating surrounding tumor cells even with lower HER2 expression, the technical basis for Enhertu's historic HER2-low breast cancer breakthrough; (3) DAR raised to 7–8 — higher drug loading per molecule without additional toxicity due to Linker stability.

China ADC technical gaps: self-synthesized patent accumulation for high-activity payloads (topoisomerase I inhibitor class Dxd analogs) insufficient; high-DAR, high-hydrophilicity Linker design patent barriers remain high; ADC specialty CDMO capacity (commercial-scale HPAPI production) is globally scarce, with China-based ADC capacity under construction expected to release 2026–2028.

9.2　mRNA Technology Platform Diversification

mRNA cancer vaccines: neoantigen vaccines (personalized mRNA cancer vaccines). Moderna/BMS mRNA-4157 (V940, melanoma adjuvant treatment) Phase 3 (combined with Keytruda) showed statistically significant DFS improvement in high-risk melanoma — if ultimately successful, will pioneer commercial mRNA cancer vaccine precedent. Domestic: StemVax, Abogen, CanSino have initiated early clinical studies.

mRNA protein replacement therapy for rare diseases: Translate Bio (Thermo Fisher/Sanofi) mRNA cystic fibrosis therapy via inhaled LNP-mRNA to restore CFTR protein function. mRNA therapy vs. AAV gene therapy: mRNA does not integrate into genome (no insertional mutagenesis risk), can be repeatedly administered, shorter manufacturing cycle; AAV achieves durable long-term expression (single dose lasting years). Both will coexist targeting different disease characteristics.

9.3　Bispecific Antibody Technology Platforms

Main technology formats: Knob-into-hole (KiH, CH3 domain steric hindrance forced pairing of two different heavy chains), BiTE (tandem scFv, short half-life requiring continuous infusion — exemplified by Blincyto from Amgen), IgG-like formats (CrossMab etc., long half-life, subcutaneous injectable).

Trispecific antibody technology (TCB: T cell bispecific) is currently mainly in academic research stage, with a few candidates entering Phase 1; represents the frontier of antibody engineering.

9.4　AI-Assisted Drug Discovery

AlphaFold2/3 revolution: compressed protein structure prediction from months to hours; accuracy approaching experimental resolution (X-ray crystallography/cryo-EM). Unprecedented expansion of computable druggable target range for virtual screening.

XtalPi (NASDAQ: XPFS): Quantum mechanics simulation and AI-based drug molecule design platform, providing crystalline form prediction, ADMET prediction, and molecule generation services. Insilico Medicine: End-to-end AI drug R&D company; AI-discovered candidate ISM001-055 (IPF target TNIK inhibitor) has reached Phase 2 — one of few companies with complete AI-discovery + AI-design + AI-clinical planning integrated pathway. Global AI pharma financing approximately $5 billion in 2023.

AI pharma limitations: Target biology validation still requires cell/animal model experiments; training data quality determines prediction precision; whether clinical success rate improves vs. pre-AI approaches remains statistically unverified at scale.

9.5　PROTAC (Targeted Protein Degradation)

PROTAC principle: E3 ligase + target protein ligand, degrading disease-causing protein via ubiquitin-proteasome system. Advantages: can degrade "undruggable" targets; overcome point mutation resistance. Challenges: large molecular weight (600–1000 Da), exceeding Lipinski's Rule of Five ideal oral absorption range.

Global leader Arvinas (NASDAQ: ARVN): ARV-110 (AR target PROTAC, prostate cancer) and ARV-471 (ER target PROTAC, breast cancer) both in Phase 3. Domestic: Kineta, Lipin Pharma and others with PROTAC pipelines.

9.6　Gene Editing and Cell Gene Therapy

CRISPR/Cas9: Casgevy (exagamglogene autotemcel, Vertex/CRISPR Therapeutics) FDA approved December 2023 — world's first approved CRISPR ex vivo editing therapy (sickle cell disease + TDT). Chinese academic foundations (Peking University, CAS CRISPR system research) are world-class; commercial pipeline development lags. Domestic companies HuihuiAnkang, EdiGene in early clinical.

AAV gene therapy: Commercially approved for RPE65 retinal dystrophy, SMA (Zolgensma), and hemophilia B (Hemgenix). Chinese enterprise AAV therapy development in early clinical; AAV manufacturing capacity globally scarce.

9.7　Nucleic Acid Drugs (siRNA/ASO)

siRNA: Alnylam Pharmaceuticals leads RNAi commercialization (Givlaari/Oxlumo/Inclisiran etc.). Inclisiran (once or twice yearly subcutaneous injection for PCSK9 reduction) expands siRNA from rare diseases to common chronic diseases.

China out-licensing case: Shimai Biopharmaceutical's siRNA licensed to Novartis — $185 million upfront (largest single nucleic acid drug out-licensing transaction from China in 2024), marking international recognition of domestic siRNA technology platform.

ASO: Spinraza (nusinersen, Biogen) for SMA validated the technology; applied in Huntington's disease early clinical.

9.8　Domestic Technology Innovation Bottleneck Analysis

Target originality insufficient: Most domestic innovative drug targets come from tracking overseas published literature rather than original domestic discovery. True first-in-class target discovery proportion remains limited; BioAtla's EGFR×HER3 bispecific ADC is one of the few exceptions.

CMC capability accumulation: CMC is a frequently encountered barrier in FDA review for Chinese drug filings — process consistency validation, analytical method development, quality standard setting require multi-product FDA/EMA review experience accumulation that remains relatively limited domestically.

Clinical endpoint selection and statistical design: International multisite trials (MRCT) design requiring unified protocols, multi-country regulatory communication, and cross-cultural project management — accumulated only in a few companies (BeiGene, Legend) with global Phase 3 experience.

Regulatory science soft power: China's ICH membership, participation in WHO innovative drug evaluation frameworks, and technical dialogues with FDA/EMA are accumulating systematic regulatory interoperability experience — no less important than any individual new technology breakthrough, a hidden but critical component of China's innovative drug out-licensing capability building.

9.9　Digitalization and Intelligent Manufacturing in Innovative Drug Production

Continuous Manufacturing (CM): Traditional batch manufacturing vs. continuous manufacturing — CM achieves continuous material flow, significantly improving efficiency, reducing material waste and equipment occupation, with real-time process monitoring (PAT) enabling inline quality assurance. Kelun-Biotech has deployed continuous flow chemistry reactors (Flow Chemistry) for scale API synthesis.

Digital twin and MES: WuXi Biologics is advancing digital twin applications in CHO cell culture platforms. FDA's increasing Data Integrity audit requirements make systems-level data traceability a basic condition for passing FDA audits.

Bioinformatics and genomics tools: Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics are providing cellular-resolution understanding of tumor microenvironments. Domestic AI pharma companies (XtalPi/Insilico) are actively integrating multi-omics data to improve AI model target prediction and molecular generation accuracy.

9.10　International Technology Gap Assessment

Patent quality and quantity: Domestic biopharmaceutical patent applications rapidly increasing (approximately 80,000–100,000 in 2024), but high-quality international patents (PCT filings, US granted patents) proportion remains relatively low.

Publication impact: China's biomedical paper publication count exceeded the US around 2020, but high-citation articles and Nature/Science/Cell top journal papers proportion remains lower than the US — basic research originality depth remains a gap, but closing rapidly.

Talent return accelerating: Post-2020, overseas Chinese scientists' rate of returning to start or join companies has notably increased. This cohort (from Genentech/Regeneron/Moderna and top US universities) is driving China's second Biotech entrepreneurship wave (2021–2025), bringing global top-tier R&D thinking and international collaboration networks.

Comprehensive assessment: China innovative drug technology in ADC/bispecifics/GLP-1 has entered global second-tier front; AI pharma tools application is approaching global leading level; target discovery, gene editing, and nucleic acid drugs remain in catch-up mode; CMC and regulatory science are relatively weak spots requiring real-world FDA/EMA filing experience to rapidly strengthen.

Chapter 10　Risks and Challenges

10.1　Medical Insurance Negotiation Price Pressure

The first major structural risk in China's innovative drug commercialization is the ongoing price pressure inherent in the medical insurance negotiation system. The 9th (2024) negotiation achieved approximately 73.5% success rate, approximately 63.5% average price reduction, cumulative reimbursement over RMB 35 billion, driving related drug sales exceeding RMB 51 billion.

Structural contradiction between price reduction pace and R&D returns: A single innovative drug's 10–12 year development cycle at over $1 billion cost means the approximately 60%+ price reduction upon entering medical insurance formulary makes the China market peak sales potential far below comparable US products.

Long-term pressure from dynamic adjustment: The formulary's annual dynamic adjustment mechanism means already-reimbursed drugs face risks of further price reductions in renewal negotiations.

Pricing dilemma: In License-out negotiations, if China's local reimbursement price is very low, it may lower MNC's total global market potential estimates for the product, compressing offered upfront and milestone totals.

10.2　VBP Policy Potential Extension Risk

Current policy provides clear innovative drug VBP exemption ("VBP does not include innovative drugs"), but this protection has boundary ambiguities:

Biosimilar VBP extension: Some regions have begun biosimilar VBP discussions. Whether domestic PD-1/PD-L1 monoclonals will enter VBP scope following patent expiry is one of the most closely watched policy risks.

Policy boundary blurring around patent expiry: Imatinib (Gleevec) post-patent VBP compression demonstrates the inevitability of "patent expiry + generic flood → VBP." As domestic innovative small molecule targeted drugs approved in 2010–2015 enter their patent expiry cycle (approximately 2025–2030), their VBP risk will become increasingly visible.

10.3　Clinical Failure and R&D Pipeline Risk

Overall Phase 1-to-NDA approval success rate approximately 7–10%. ADC Phase 3 failure rate approximately 65%; PD-1 monotherapy Phase 2/3 failure rate in unselected patients is also not low.

ADC clinical failure characteristics: Common causes include target selection errors (insufficient antigen expression), Linker stability issues (premature payload release in plasma), patient selection strategy errors (insufficient biomarker screening), and toxicity management difficulties (interstitial pneumonia, hematologic toxicity).

Me-too pipeline commercialization risk: Large numbers of domestic Biotech pipelines concentrated in validated targets (PD-1/EGFR/HER2/CDK4/6) cannot differentiate from pioneer products.

10.4　BIOSECURE Act and Geopolitical Risk

BIOSECURE Act background: US Congressional legislation restricting US federal funds from flowing to certain foreign biotech companies deemed to pose "national security risks" — specifically targeting WuXi AppTec, WuXi Biologics, BGI, and others.

Direct impact: If enacted and effective, Chinese CXO companies' US client contracts would be restricted. WuXi AppTec's 2024 revenue approximately RMB 39 billion, with US business accounting for approximately 40–50% — losing this portion would be a material revenue impact.

Response strategies: Multi-location deployment in Ireland, Singapore, and Europe; expanding European/Asia-Pacific client coverage; focusing on Chinese domestic Biotech clients' internal circulation demand.

10.5　Overseas Approval Barriers

Chinese clinical data FDA/EMA acceptability issues: Racial difference data requirements, clinical endpoint design considerations, and CMC standard differentials frequently become obstacles in FDA review. The toripalimab FDA nasopharyngeal carcinoma approval path (China-specific high-incidence indication, FDA accepted Asian-predominant trial data) has limited replicability for most other indications.

10.6　Competitive Landscape Risk

MNC intensifying China localization: AstraZeneca's deepest China R&D investment (3,000+ China R&D staff), directly competing for the same patient and indication space as domestic Biotechs.

Biotech valuation bubble correction: Some HK 18A Biotechs saw 70–90% market cap decline from 2021 peak, creating refinancing difficulties for companies with limited cash reserves.

10.7　IRA Transmission to MNC Return Expectations

IRA allows Medicare drug price negotiation; pembrolizumab (Keytruda) is confirmed on the negotiation list. MNCs will incorporate US market pricing prospects into return modeling when evaluating Chinese asset License-in. If US government pricing controls on major products reduces MNC total return expectations, it will reduce upfront and milestone totals they are willing to offer.

China innovative drug companies' response direction: market diversification beyond the US; strengthening EU/EMA direct commercialization (BeiGene already directly selling zanubrutinib in multiple European countries).

10.8　Supply Chain Security and Production Continuity Risk

Critical raw material import dependency: Key ADC payload precursors (MMAE precursors, maytansinoid DM1 derivatives) are primarily held by US companies (ImmunoGen); single-use bioreactors (Sartorius, Cytiva/GE Healthcare) and culture media (Thermo Fisher) predominantly imported from US/Europe.

Cold chain logistics and ultra-low temperature storage: Biologic innovative drugs (mAb/ADC/CAR-T) require strict storage conditions — CAR-T requires -80°C (-196°C liquid nitrogen) throughout transport and storage.

Patent expiry impact: PD-1 monoclonal substance patents in China typically protected until 2030–2035; after expiry, biosimilars will compete. Companies are responding by continuously investing in next-generation products (bispecifics/ADC/GLP-1) to replace maturing products.

10.9　Regulatory and Compliance Risk

Tightening global drug regulatory environment: FDA showing stricter review orientation in several areas: more rigorous post-marketing confirmatory study requirements for accelerated approval drugs; higher evidentiary requirements for products approved on surrogate endpoints.

Data compliance and data security: China's Data Security Law and PIPL (Personal Information Protection Law) impose strict restrictions on cross-border transmission of medical data (including genetic data and clinical trial data). This creates practical operational barriers for domestic Biotechs providing patient-level clinical data to overseas MNC partners in License-out negotiations.

10.10　Financing Tightening and Biotech Survival Pressure

As of end-2024, a significant proportion of the 70+ HK Chapter 18A biotech companies face cash reserve burn-rate warnings of 12–24 months. Funding is concentrating toward mid-to-late-stage projects with clinical data; early-stage undifferentiated pipeline valuations are significantly compressed.

A-share STAR Market biotech companies face continuous profitability requirements or sustained R&D investment thresholds; companies with long-term low revenue growth and continuous losses may face STAR Market delisting new rules pressure (e.g., consecutive 3-year negative net assets conditions).

10.11　Comprehensive Risk Assessment Matrix

High probability, high impact: Medical insurance negotiation price reductions (confirmed annual mechanism), PD-1/me-too pipeline price war (structural competition);

Medium probability, high impact: BIOSECURE Act formal passage (specific terms and timeline still uncertain), ADC/GLP-1 large out-licensing deal milestone non-fulfillment (dependent on clinical success rate);

Low probability, extremely high impact: China-US biotechnology comprehensive decoupling (extreme scenario beyond current policy trajectory), major innovative drug safety crisis;

Manageable, persistently present: Patent expiry cycles (manageable via new indications/next-generation products), CMC obstacles in FDA review (gradually reducing with real-world experience accumulation).

Chapter 11　2026–2030 Forecasts

11.1　Market Size Forecasts and Scope Clarification

Baseline scenario (neutral CAGR 15–18%, Scope 1, pure innovative drugs):

2024 base approximately RMB 160 billion (midpoint of RMB 150–170B range):

Year	Forecast (neutral 16.5% CAGR)	Notes
2025E	~RMB 170–200 billion	Validated range (mazdutide commercialization started, NRDL quantity-price restructuring)
2026E	~RMB 200–233 billion	Hengrui/Innovent/BeiGene multi-product ramp, GLP-1 weight loss NRDL expected
2028E	~RMB 270–320 billion	BL-B01D1/SKB264 approval if successful would expand domestic ADC market
2030E	~RMB 380–420 billion	Neutral forecast unchanged

Aggressive scenario (CAGR 24.1%, Scope 2 base of RMB 257.6B): By 2030 could reach RMB 900–1,000 billion. This forecast highly depends on medical insurance payment expansion and rapid GLP-1 rollout; difficult to achieve.

Conservative scenario (CAGR 12%): By 2030 approximately RMB 280 billion (Scope 1), main concern being ongoing medical insurance pricing compression weakening innovation returns.

This report judges the neutral scenario most likely to be achieved: China innovative drug market (Scope 1) approximately RMB 380–420 billion by 2030, approximately 2.4–2.6× expansion from 2024.

11.2　License-out Out-Licensing Trend Continuation

2024's $60B was the first milestone; 2025's $135.6B confirms this is a structural trend, not a one-off peak.

Keytruda patent expiry forcing structural demand: Pembrolizumab's US patent expiring around 2028 will cause biosimilars to significantly erode Keytruda's share. Merck needs to fill the post-Keytruda era pipeline gap, and Chinese Biotechs' ADC platform and bispecific pipelines are among the world's richest current supply sources.

Other MNC pipeline refill needs: BMS (Revlimid expiry income gap), Pfizer (COVID product revenue decline, restructuring), AbbVie (Humira post-expiry entry into growth pressure period) all face pipeline gaps from core product patent expirations.

Chinese first-in-class pipelines maturing: Several currently in Phase 2/3 Chinese first-in-class candidates (Akeso ivonescimab/Innovent IBI363/BioAtla BL-B01D1) will produce critical clinical data in 2025–2028, potentially triggering new major License-out opportunities if results are positive.

Revised using 2025 actuals (upfront payments ~$7B) as baseline: projected 2026–2030 annual average upfront cash received $5–8 billion, total agreement value (including milestones) annual average $500–1,000 billion per year — significantly above the pre-2025 forecast of $2.5–3.5 billion. Out-licensing is evolving from "License-out dominated" toward parallel "co-development + independent commercialization" models; Chinese companies are beginning to take joint global Phase 3 responsibilities (BioAtla + BMS on BL-B01D1 US Phase 3 as the representative case).

11.3　2030 Outlook for Three Structural High Grounds

ADC track: Global ADC market 2030 approximately $30–35 billion (CAGR ~16–18%). China's global ADC share: shifting from technical follower to partial leader (BioAtla in EGFR×HER3 direction). If BL-B01D1 Phase 3 succeeds, China will enter an era of co-developing with BMS for global Phase 3, marking Chinese ADC's full transition to genuine global co-development.

GLP-1 track: Global GLP-1 market 2030 could exceed $150–200 billion. China GLP-1 market 2030 projected approximately RMB 33 billion (type 2 diabetes RMB 15.5B + obesity/overweight RMB 17.3B). Key variable: medical insurance inclusion timeline for weight loss indication (expected 2026–2028 window).

Bispecific/trispecific track: Bispecific global market 2030 approximately $200–300 billion (from current ~$5–6B). Ivonescimab (PD-1/VEGF) global Phase 3 results are the key validation milestone for Chinese bispecifics.

11.4　CAR-T Quantity-Price Restructuring

Medical insurance inclusion analysis: RMB 1–1.2 million/dose → expected post-insurance-negotiation reduction to RMB 200,000–400,000/dose (60–80% cut), but simultaneously driving massive patient accessibility improvement. Off-the-shelf CAR-T if successfully validated in 2026–2028 would overturn current autologous CAR-T's individualized high-cost manufacturing model, with potential cost reduction to RMB 100,000–200,000/dose.

11.5　CXO Industry Repositioning

BIOSECURE Act if enacted: China CXO needs to transition from US business contraction. Alternative pathways: Europe/Japan/South Korea client expansion; domestic Biotech internal circulation demand (domestic Biotech R&D outsourcing unaffected by BIOSECURE Act); global facility deployment (WuXi Biologics Ireland/US). CXO overall global market CAGR approximately 11%, projected $170B by 2030.

11.6　Regulatory Environment Outlook

"15th Five-Year Plan" (2026–2030) expected policy directions: continued improvement in review efficiency (NDA target under 6 months for Priority Review); medical insurance payment reform deepening (value-based payment pilot for gene therapy/CAR-T); international regulatory convergence (gradual data mutual recognition under ICH framework, particularly for China-endemic high-incidence cancer indications); "made in China" substitution continuing for key raw materials.

11.7　Investment Logic: Alpha and Beta Allocation

Alpha opportunities (individual stock/sector excess return directions):

ADC platform-type companies (simultaneously holding multiple R&D pipelines + technology platform licensing capabilities, replicating Kelun-Biotech model) — most certain alpha direction in 2026–2030. GLP-1 next-generation (GLP-1/GCG/GIP triple target or GLP-1+cardiovascular new targets). Autoimmune first-in-class (IL-4/13, TSLP, OX40L, IL-31, BTLA new targets).

Beta opportunities (broad industry system uplift benefits):

Medical insurance negotiation quantity-price restructuring bringing innovative drug overall volume growth; CDMO internal circulation demand (domestic Biotech R&D outsourcing growth); innovative drug accelerated review driving registration service CRO growth.

Core risk reminders: License-out transaction "paper prosperity" risk — upfront payments are confirmed income, but milestone payment actual fulfillment depends on clinical success. PD-1/me-too ADC pricing spiral — if same-ization intensifies, medical insurance negotiation price reductions will continue expanding, driving single me-too product long-term returns to continuously decline. Geopolitical uncertainties (BIOSECURE Act formal passage, US tech export controls extending to biopharmaceuticals).

11.8　Out-Licensing Path Evolution

2024 mainstream model: "China discovery + MNC development and commercialization" — Chinese Biotechs provide innovative molecules, MNCs handle global Phase 2/3 and commercialization; China companies receive only upfront + milestones with limited control over the final product.

2026–2030 emerging trend: "Chinese company self-directed global development" — exemplified by BeiGene (zanubrutinib self-directed US/EU commercialization) and Legend Biotech (Carvykti co-commercialized with J&J while retaining partial control). This transition requires building commercialization teams, regulatory affairs capabilities, and market access capabilities in US/Europe — extremely high threshold, but potential returns (retaining larger share of commercial benefits) correspondingly higher.

China-US dual IND (simultaneous IND) proportion projected to rise from approximately 25–30% in 2024 to approximately 40–50% by 2030.

11.9　China Innovative Drug International Standing Quantitative Forecast

By 2030, Chinese Biotechs' share of global active clinical pipelines projected to increase from approximately 12–15% in 2024 to 18–22%, surpassing Europe to become the world's second-largest clinical pipeline source (behind only the US). In ADC, the proportion of global commercialized ADCs involving Chinese molecules (including MNC-developed Chinese-origin molecules post-License-out) projected to reach 15–20%.

BeiGene: Potentially entering global Biotech top 15–20 by revenue by 2030 (zanubrutinib + new pipeline); 2030 revenue could exceed $10 billion.

Hengrui: 20+ overseas licensing collaborations potentially cumulated in 2025–2030; total agreement value (including milestones) could exceed $50 billion. Hengrui's model is "China commercialization + overseas licensing" dual-drive, distinct from BeiGene's "global self-commercialization" — two different out-licensing strategic choices.

M&A integration expected wave: Large MNC acquisitions of Chinese Biotechs (most likely in ADC or CAR-T); large domestic pharma acquiring small Biotechs for early pipeline; horizontal consolidation between complementary Biotechs to reduce operating costs.

11.10　Science Ethics and Sustainable Development

Clinical trial ethics: China's large-scale clinical trial system's efficiency and speed advantages must be premised on strict subject protection, full informed consent, and effective independent ethics committee oversight. ICH E6(R3) new guideline implementation will further raise clinical research ethical standards.

Innovative drug accessibility: High-price innovative drug accessibility (especially CAR-T, rare diseases) is the social responsibility dimension of sustainable development of the innovation ecosystem. CAR-T extreme prices still require medical insurance system further innovation (value-based payment) to achieve truly broad accessibility.

Environmental impact: Large-scale biological fermentation production and chemical synthesis (especially ADC toxic payload handling) generate environmental disposal requirements. Chinese biopharmaceutical CDMO environmental compliance requirements are aligning with international standards.

11.11　Digitalization and Precision Medicine Impact on Future Markets

Liquid biopsy, multi-omics testing, and AI-assisted diagnostics' continued proliferation will profoundly impact the 2026–2030 innovative drug market:

Market expansion: Earlier detection of tumor recurrence (liquid biopsy MRD detection) drives more neoadjuvant and adjuvant treatment demand, expanding applicable patient populations for ADC/immunotherapy. Enhertu-type ADC post-surgical adjuvant treatment research (HER2+ breast cancer DESTINY-Breast05 etc.) if successful could open vast new early-stage indication markets.

Precision stratification deepening: Increasingly refined tumor molecular profiling (from gene mutations to protein expression to epigenetics) makes innovative drug indications increasingly precise with higher pricing. This trend helps first-in-class molecules with differentiated targets avoid VBP pressure.

Patient enrollment efficiency revolution: AI-driven patient enrollment platforms projected to significantly shorten Phase 3 clinical trial enrollment times in 2026–2028, lowering R&D costs, accelerating Chinese Biotech product market entry timelines, and in turn improving out-licensing negotiation data readiness and upfront payment negotiation capability.

Chapter 12　Conclusions

12.1　From Generics to Innovation: The Hardest Stretch Has Been Completed

China's innovative drug industry took thirty years to evolve from a pharmaceutical production system nearly entirely dependent on generics into an innovative ecosystem now exporting original molecules globally. Looking back on this path: 1990s raw API export was the starting point, 2015 review reform was the watershed, and 2024's License-out exceeding $60 billion is the phased historic milestone.

But this report does not wish to use "China's innovative drug industry has risen" to characterize the current moment — a more accurate expression is: China's innovative drug industry is in a transition phase from "follow-on innovation" to "original innovation," and this transition is far from complete. ADC out-licensing's prosperity is built on genuine technical accumulation in Chinese conjugation technology; GLP-1 out-licensing is built on domestic Biotechs' years of investment in metabolic drug R&D. These are not bubbles, but real industrial capability improvements. But simultaneously, China's first-in-class original capabilities for discovering novel targets and defining novel indications remain on the path of catching up to international top-tier levels.

12.2　Three Key Bets for 2026–2030

Bet 1: Akeso ivonescimab (PD-1/VEGF bispecific) global Phase 3 results. If ivonescimab shows OS advantage over standard treatment (PD-1 monotherapy + bevacizumab) in global NSCLC Phase 3, it will be a milestone validating Chinese bispecifics globally, triggering Sanofi's $7.569 billion milestone payments. If it fails, it serves as a systemic warning for the PD-1/VEGF bispecific technical path.

Bet 2: BioAtla BL-B01D1 (EGFR×HER3 bispecific ADC) Phase 3 results. BMS paid $800 million upfront for this core asset; BL-B01D1's success or failure will serve as the industry's benchmark for judging "whether Chinese ADC molecular quality is in the same tier as Enhertu." Success will greatly elevate China ADC's global pricing power; failure will cause the market to reassess the technical maturity of domestic ADC pipelines.

Bet 3: Innovent mazdutide (GLP-1/GCG dual target) global development partnership with Lilly. If mazdutide achieves large-scale commercialization in China after approval, and in weight loss indication achieves clinical data comparable to Lilly's Zepbound, it will become the best demonstration case for Chinese GLP-1 going global.

12.3　Long-Term Trend Assessment of Industry Structure

Concentration increase will happen, but on a slower timeline than imagined. China innovative drug CR10 currently approximately 40–45%, will trend toward 50–55% over the next five years. The catalysts for rapid concentration are large pharma M&A integrations and involuntary pipeline sales due to financing exhaustion.

Commercialization capability becomes the key differentiator. In the past five years, differentiation was "who has better targets"; in the next five years, differentiation is increasingly "who can convert clinical advantage into commercial scale." Hospital formulary access speed, patient education system building, DTP pharmacy network deployment, and overseas direct commercialization capability will become the second-order competitive moats of innovative drug companies.

12.4　Supply Chain Identification Data Perspective for Innovative Drugs

Throughout the research into China's innovative drug industry, midstream supply chain CDMO, CMO, and specialty conjugation factories are a long-neglected but increasingly important value creation segment — particularly as domestic ADC pipeline density increases, ADC specialty CDMO capacity scarcity has become a real bottleneck affecting multiple Biotechs' clinical progress. Tianxia Gongchang (www.tianxiagongchang.com) leverages approximately 4.8 million genuinely operating factory data covering API manufacturers, formulation CMOs, ADC conjugation mid-sized factories, and other innovative drug upstream support ecosystems. Its "genuinely operating factory" verification logic, distinct from pure business registration data, provides a unique data perspective for innovative drug supply chain supplier due diligence and partner factory screening. As China's innovative drug commercialization scale continues expanding, supply chain identification and management capabilities will become an important component of Biotech operational efficiency.

12.5　Final Judgment

This report judges: China's innovative drugs will form at least 5–8 self-developed products (including co-commercialization) directly commercially sold in the US/Europe before 2030; License-out cumulative upfront payments will exceed $20 billion by 2030 (2020–2030 total); China innovative drug's share in the global innovative drug value chain will increase from current approximately 5–7% to 10–15%.

12.6　Action Recommendations for Market Participants

For innovative drug companies: In the 2024–2028 window period, the primary task is differentiation — both technical differentiation (ADC new targets/bispecific new combinations/next-gen GLP-1) and indication differentiation (China-endemic high-incidence cancer global data accumulation). Parallel China-US dual-track IND, incorporating overseas registration into early R&D design, is the key operational approach to maintaining first-mover advantage.

For CXO companies: BIOSECURE Act uncertainty means geographic diversification is urgent — establishing compliant production facilities in Ireland, Singapore, or Eastern Europe as alternative supply options for US clients; simultaneously expanding Chinese Biotech client coverage.

For investors: Distinguishing alpha (individual stock excess return) from beta (sector systematic rise) is the key cognitive framework for innovative drug investing over the next five years. ADC platform companies, next-gen GLP-1, and autoimmune first-in-class are the clearest alpha opportunities; CDMO internal circulation demand and medical insurance negotiation volume-price restructuring are relatively clear beta directions.

12.7　Report Limitations and Research Outlook

Limitations: Some 2024 enterprise financial data are estimated values (where official annual reports were not yet published); global MNC China-specific data adopts inference methodology due to disclosure limitations; policy variables (medical insurance negotiation price reductions, BIOSECURE Act progress) carry high uncertainty.

Future research directions: sub-track (ADC/GLP-1/bispecifics) market competition model building; CXO sector financial impact quantification under different BIOSECURE Act scenarios; Chinese Biotech out-licensing deal milestone fulfillment rate statistical analysis; empirical research on AI pharma's actual impact on R&D efficiency.

China's innovative drug industry's ultimate question is not just "can they out-license," but "can they become contributors to global biomedical knowledge" — can they discover novel targets that change humanity's understanding of diseases, can they pioneer treatment approaches never seen globally, can they occupy original, equal, and sustained positions in the global biomedical community. The answer requires not just capital and technology, but time and scientific accumulation. China's innovative drugs have currently completed the hardest stretch — the leap from generics to follow-on innovation — and the next stretch, perhaps longer than the past thirty years, has a clear direction. In the ADC, GLP-1, and bispecific antibody tracks, China is no longer a bystander, but a pricer, contributor, and challenger. This is a genuine historical transformation worth recording accurately, and worth taking seriously. The rise of China's biopharmaceutical scientist community, continuous improvement of the policy system, and ongoing maturation of the industrial ecosystem are together pushing this once-apprentice pharma nation toward the center of the global innovative drug map. The road ahead is long, but 2024's $60 billion is already the most powerful historical footnote.

Data Sources

Based on the factory database of the Tianxia Gongchang platform (www.tianxiagongchang.com), supplemented by the following public data sources:

• Hengrui Medicine (600276) 2024 Annual Report and investor relations announcements
• BeiGene (688235/BGNE/6160 HK) 2024 Annual Financial Report
• Innovent Biologics (1801 HK) 2024 Annual Results Presentation
• Junshi Biosciences (688180) 2024 Annual Report
• Akeso (9926 HK) 2024 Annual Report
• BioAtla (688506) 2024 investor relations announcements (BMS upfront payment related)
• Kelun-Biotech (6990 HK) 2024 annual report and prospectus
• Legend Biotech (LEGN) 2024 Annual Report (SEC 20-F)
• RemeGen (688331/9995 HK) 2024 interim and annual reports
• National Healthcare Security Administration 2024 National Basic Medical Insurance Drug Formulary Adjustment Press Conference
• NMPA 2024 Annual Drug Review Report
• PharmCube (ByDrug), DrugTimes January 2025: China Innovative Drug Out-licensing 2024 Year-End Review
• Jiemian News, Yicai, 21st Century Business Herald Q1 2025 innovative drug enterprise performance reports
• Suzhou Industrial Park Management Committee official website BioBAY industrial data (2024)
• Huatai Securities, CICC, Founder Securities 2024 Pharmaceutical Industry Research Reports
• Global pharmaceutical company annual reports (Pfizer/Merck/Eli Lilly/Novo Nordisk/AstraZeneca/Roche/Novartis/J&J/AbbVie/BMS/Takeda)
• WHO, ICH official website relevant technical guidelines and policy documents
• US FDA official website 2024 Annual New Drug Approval Statistics